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ABSTRACT OF THE DISSERTATION
Novel Contrasts in Photoacoustic Tomography
by
Ruiying Zhang
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2016
Professor Lihong V. Wang, Chair
Photoacoustic tomography (PAT) combines rich optical contrast and high ultrasonic resolution in
optically scattering tissue at depths. Taking advantage of its 100% sensitivity to optical absorption,
PAT has been widely applied to structural, functional and molecular imaging, with both
endogenous and exogenous contrasts, at superior depths than pure optical methods. This
dissertation explores novel absorption contrast mechanisms of PAT based on optical/thermal
patterns, endogenous cellular chromophores, nanoparticles, small-molecule dyes and geneticallyencoded proteins. With these novel contrasts, the proof-of-concept applications of PAT have been
extended to include homogenous flow measurements, targeted angiogenesis imaging and therapy,
label-free white blood cell imaging, 3D-whole-organ cell nuclei imaging with a subcellular
resolution, and in vivo neural activity imaging with voltage/calcium-sensitive indicators.
Specifically, Chapter 1 introduces photoacoustic microscopy (PAM) and photoacoustic computed
tomography (PACT) systems and discuss the motivation of the dissertation.
Chapter 2 describes two photoacoustic (PA) flow measurement methods with optical and thermal
patterns, which are applicable to homogenous flowing medium. In the first method, a Doppler
frequency shift in PA signals of the flow was detected and used to calculate flow speeds. In the
ix

second method, unique features in an externally imposed thermal pattern of the flow, captured by
repeated B-scans along the flow direction with a PAM system, revealed different flow speeds.
Chapter 3 explores the unique PA contrast of macrophages, an important type of white blood cells.
Macrophages were imaged by PAM without any label, and their measured PA spectrum was
distinctive from the hemoglobin spectrum, so they can be potentially differentiated from red blood
cells in the blood stream. Next, with a microtomy-assisted PAM system, cell nuclei distribution in
whole organs, including mouse brain and mouse lung, were imaged with subcellular resolution.
Chapter 4 introduces a type of target copper nanoparticles, which are less expensive and more
biocompatible than its counterpart gold nanoparticles. The PA signals of neovasculature in the
mouse flank were enhanced by the ανβ3-targeted copper nanoparticles. Moreover, the work shows
the first example of a systemically targeted antiangiogenic drug delivery with a photoacoustic
contrast nanoparticle in vivo.
Chapter 5 demonstrates the voltage imaging capability of PA. A voltage sensitive dye with
sufficient signal change was discovered and used as a PA voltage indicator for the first time. The
mechanism was characterized through both PA imaging and spectroscopic methods. Its use was
explored in a mouse epilepsy model and cortical electrical stimulation model in vivo. Finally, the
deep imaging potential of PA was realized by imaging the voltage response of cells under 4.5 mm
thick slice of rat brain tissue using a PACT system.
Chapter 6 proves the neural calcium imaging capability of PA with a genetically encoded calcium
indicator. In a fly model, I ambiguously demonstrated for the first time that PA can be used to
imaging neural activities in the fly brain without the interference signals from hemoglobin. In the

x

a live-mouse-brain-slice model, I successfully demonstrated the deep imaging capability of PA for
calcium imaging by imaging through a 2-mm-thick scattering medium with a PACT system.

xi

Chapter 1 Introduction
1.1 Introduction to Photoacoustic Tomography
In PAT, as tissues are excited by laser pulses, laser energy is absorbed by biochromophores and
converted into heat through non-radiative relaxation. The heat is further converted to a pressure
rise through thermoelastic expansion. The initial pressure rise propagates as an ultrasound wave
in the tissue, which is referred to as a photoacoustic (PA) wave 1,2. An ultrasonic transducer or
transducer array is used to detect the PA waves, and the detected PA signals are used to reconstruct
an image that maps the original optical energy deposition and tissue. By converting photons into
ultrasonic waves, which are orders of magnitude less scattered, photoacoustic tomography (PAT),
an emerging imaging modality, can break through the diffusion limit (~1 mm depth) by
capitalizing on the low acoustic scattering in tissue. Moreover, the image resolution and
penetration depth of PAT are highly scalable with ultrasonic frequency, which provides an
unprecedented opportunity to bridge the gap between microscopic and macroscopic images.
Based on the image formation methods, PAT has two major implementations. The first combines
mechanical scanning of a focused single-element ultrasonic transducer with direct image
formation, and is commonly used in PAM. The second combines parallel detection by a multielement ultrasonic transducer array or a mechanical/electronic scanning equivalent with image
reconstruction, and is used in PACT. In both PAM and PACT, the PA amplitude is proportional
to the optical absorption coefficient of the absorber in units of m –1, to its non-radiative quantum

1

yield (approximately equal to 1 – the fluorescence quantum yield if the photochemical channel is
negligible), and to the local optical fluence (or exposure) in the unit of J/m 2.

1.2 Motivation
By using endogenous contrasts, PAT can provide structural and functional information, based on
the absorption of DNA & RNA3, cytochromes4, hemoglobin5, melanin6, and lipids7 at optical
wavelengths ranging from ultra-violet (UV) to near-infrared. Among these absorbers, hemoglobin
and melanin have relatively strong absorption coefficients, and they have been widely used in the
study of cancer and hemodynamic-related parameters. Relatively weak absorbers at the visible
wavelength, such as DNA/RNA and cytochromes, have been much less explored. However, their
untapped potential could be fundamental for building a complete picture of tissue properties and
dynamic physiological processes. Discovering more endogenous contrasts and advancing
endogenous-contrast-based PAT to preclinical/clinical research are major goals of this work.
While endogenous contrasts are useful tools, they provide access to a limited range of biomedical
applications8. Exogeneous contrasts, including nanoparticles, dyes, and genetically-encoded
proteins, can enable the visualization of biological processes of interest and are still highly desired.
In the imaging of exogenous contrasts, endogenous contrasts often serve as the background signals,
making it difficult to distinguish them. Therefore understanding the merits of exogenous contrasts,
and the difficulty they present, is a rewarding and challenging topic.
This dissertation aims to address the need and challenges presented above, and explore novel
contrasts of PAT based on both endogenous and exogenous contrasts.

2

Chapter 2 Photoacoustic Flowmetry in
Homogenous Media
This chapter describes techniques for homogenous flow measurement. When the absorber is at
high concentration or its size is small enough, it cannot be resolved spatially due to the limited
bandwidth of the transducer. With previous flow measurement methods, the medium was
considered to be a static homogenous continuum9. In this chapter, we develop methods to measure
the flow speed of a homogenous medium, and demonstrate PA Doppler effect in a homogeneous
medium and the feasibility of calculating the flow speed based on a thermal pattern encoded in
blood flow in vivo. Work in this chapter has been published in Applied Physics Letters9 and Optics
Letters10.

2.1 Structured-illumination Photoacoustic Doppler
Flowmetry of Axial Flow in Homogeneous Scattering
Media
2.1.1 Background
Flow speed measurement plays an important role in biomedical research, such as the study of
tumor and cardiovascular diseases. In biomedical imaging, Doppler ultrasound flowmetry11,12,
laser Doppler flowmetry13 and Doppler optical coherence tomography14 are all valuable tools for
flow speed measurement. However, based on backscattered signals, these Doppler techniques
require particle heterogeneity in the flowing medium11-14, thus they cannot be used for flow
3

measurement of a homogeneous medium. In comparison, photoacoustic imaging, based on optical
absorption contrast15, is not intrinsically limited by the heterogeneity of the flowing medium. A
few recent studies have investigated photoacoustic Doppler (PAD) flowmetry of particle-based
phantoms16-23. It has been reported that the traditional PAD signal strength decreases and
eventually diminishes as the particle concentration increases24,25. In this paper, we propose a new
flow measurement method based on the PAD effect in homogeneous media, where the distance
between absorptive molecules is on the level of nanometers. Different from traditional PAD
implementations, which use a temporally modulated CW or tone-burst laser excitation, our method
uses a spatially modulated pulsed laser excitation to temporally modulate the received PA signals.
The modulation frequency of the received PA signals is determined by the acoustic transit time
between the neighboring pitches of the spatial modulation. Therefore, the flow of the medium
changes the acoustic transit time and thus induces a frequency shift in the received PA signals. As
in traditional PAD flow measurement16-23,26,27, the flow direction determines the sign of the
frequency shift.
In PA flow measurement of a homogeneous medium, a stationary ultrasonic detector receives
signals from the excited region of the medium, which is the acoustic source. As shown in Figure
1(a), if both the acoustic source and the medium are stationary, the PA wave from the stationary
acoustic source travels to the transducer surface at the speed of sound in the medium (~1480 m/s
in water at 20 C ). If both the acoustic source and the medium are moving, the received PA signal
will be compressed or stretched, depending on the flow direction. In the time domain, this
compressing or stretching effect can be further decomposed into two parts: the arrival time shift
induced by the moving medium and the signal duration scaling induced by the moving source. In
the frequency domain, while the arrival time shift corresponds to the phase shift at each frequency,
4

the signal duration scaling corresponds to the scaling of the frequency spectrum. Both the arrival
time shift and the signal duration scaling can be used to measure flow speed. However, using the
arrival time shift requires exact knowledge of the sound path between the acoustic source and the
transducer, which is challenging to achieve in biological tissues. By contrast, the signal duration
scaling relies only on the acoustic property of the moving source, even if the sound path between
the source and ultrasonic transducer is uncertain. In this study, we explored four methods of PAD
flowmetry of homogeneous media: (1) central frequency shift; (2) arrival time shift; (3) phase
change at each frequency; (4) temporal scaling.

2.1.2 Methods
Central Frequency Shift

Similar to traditional PAD flow measurement, if the PA signal

generated by the moving source has a central frequency with a narrow bandwidth, then the scaling
of the spectrum can be represented by its central frequency shift, from which the medium’s flow
speed and direction can be derived. In our method, the modulation frequency f 0 can be estimated
as
f 0  va / d 0 ,

(2.1)

where va is the speed of sound in the stationary medium, d 0 is the fringe pitch of the spatiallymodulated illumination.
Then, the central frequency shift can be expressed as

f PAD  f 0

vm
,
va

5

(2.2)

where vm is the flow speed of the medium projected along the acoustic beam axis. A positive
frequency shift means the medium is flowing towards the transducer, and vice versa. Note that the
PAD frequency shift in Eq. (2.2) is only half of the traditional ultrasound Doppler shift, due to the
one-way emission of the PA signals. In practice, the central frequency of the PA signal can be
estimated as the power-weighted mean frequency. 19, 20
Arrival Time Shift

This method is predicated on the assumption that both the flow speed and

acoustic property along the path are uniform. The time shift tm can be estimated by crosscorrelation between the received PA signal p1 (t ) at flow speed v1 and the PA signal p0 (t ) at a
baseline flow speed v0 . If the flight time of the signal is much longer than its duration (i.e., the
distance from the center of the illumination spot to the transducer is much larger than the size of
the illumination spot), the contribution of the signal duration to the cross-correlation can be
neglected. Thus, by finding the time delay tm that maximizes the cross-correlation between
p1 (t ) and p0 (t ) , the relative flow speed vm can be calculated as follows:

tm = argmax 

tmax

0

t

p0 (t ) p1 (t  t )dt ,

vm  va 2

t m
,
L

(2.3)

(2.4)

where tmax represents the ending point of the signal and L is the distance between the transducer
and the center of the illumination spot. A positive arrival time shift means the medium is flowing
away from the transducer, and vice versa.

6

Phase Change

Alternatively, in the frequency domain, the phase information of the cross-

spectral density function of the signal can also be used to calculate the time delay tm .21 We have

tm 

1

argS p1 p0 ( f ) ,

2 f

(2.5)

where S p1 p0 ( f ) is the cross-spectral density of the received signals p1 (t ) and p0 (t ) . After
extracting the phase from S p1 p0 ( f ) , we can then fit for the arrival time shift tm using Equation
(2.5) and calculate the flow speed using Equation (2.4).
Temporal Scaling

In the time domain, in addition to the approximate calculation method based

on cross-correlation, the flow speed can also be estimated by a more accurate temporal scaling
method. The scaling factor  m that maximizes the product of p 1 ( m t ) and p0 (t ) can be
calculated using Equation (2.6), and the flow speed is given by Equation (2.7):

 m = argmax 


tmax

0

p0 (t ) p1 ( t )dt ,

vm  (1   m )va .

(2.6)

(2.7)

A temporal scaling factor less than one means the medium is flowing towards the transducer, and
vice versa.

2.1.3 Results
Here, photoacoustic flow sensing based on the PAD effect from a homogeneous medium was
demonstrated in a laboratory setup, shown in Figure 2.1(b). A pump (Model 3386, Fisher Scientific
7

and EW-72008-00, Cole Parmer) drove the flow in a clear PVC tube (ClearFlexTM 60 premium,
8 mm inner diameter) immersed in water. Nanosecond laser pulses of 570 nm wavelength were
focused by a cylindrical lens (300 mm focal length), which generated a 3-mm-long illumination
line along the tube axis. A Ronchi ruling (50 µm pitch size) was placed above the tube, which
provided a spatial modulation of the illumination intensity. A diluted red ink solution (optical
absorption coefficient:  a  1.2 cm-1) was used as the flowing medium. The generated
photoacoustic waves propagated in the flowing medium and were detected by a flat ultrasonic
transducer (V2022 BC, Olympus-NDT). The distance between the illumination spot and the
transducer surface was approximately 5.6 cm. The PA signals from the transducer were amplified
by 40 dB and then sampled by an oscilloscope (TDS5034, Tektronix, Inc.). The recorded PA
signals were averaged for 256 times. In a second experiment with a scattering medium, the tube
was immersed in a 0.1% intralipid solution (optical scattering coefficient:  s  6.18 cm-1 at 570
nm). 22

Figure 2.1 Flow measurement based on the PAD effect in a homogeneous medium. (a) Schematic of PA
signals under different flow conditions. vs and vm are the flow speeds of the source and the medium,

8

respectively; t1 and t2 are the arrival times of signals under the two flow conditions;  1 and  2 are the
signal durations under the two flow conditions. Both the arrival time and the signal duration decrease when
vs  vm  0 (flow is towards the transducer), compared with when vs  vm  0 . (b) Schematic of
experimental setup. The homogenous flow with speed vm is excited by structured illumination, and the
generated PA signal is detected by a flat ultrasonic transducer placed in the axial direction of the tube. L
is the distance between the illumination spot and the transducer surface, and d is the illumination spot size.

Figure. 2.2(a) shows the temporal profile of a typical photoacoustic signal from a stationary
homogeneous medium, where the signal modulation is clear. The arrival time was about 37.5 µs,
which corresponded to a distance of ~5.6 cm between the illumination spot and the transducer
surface. The total duration of the signal was about 2 µs, which corresponded to an illumination
spot size of ~3 mm. As shown in Figure. 2.2(b), a faster flow (0.63 m/s) of the medium towards
the transducer induces a shorter arrival time of the signal than a slower flow (0.16 m/s), producing
a time shift in the temporal profile of the received PA signal. Correspondingly, Figure. 2.2(c)
shows the frequency spectrum of the PA signal acquired at a flow speed of 0.63 m/s. The signal
has a central frequency of 29.8 MHz with a full-width at half maximum of 9.7 MHz. According to
Eq. (2.2), the central frequency is related to the spatial modulation frequency of the illumination
pattern, the propagation speed of sound in the homogeneous medium. The bandwidth is determined
by the duration of the PA signal, which is also related to the propagation speed of sound in the
medium. A faster flow of the medium towards the transducer shortens the signal duration and
increases the central frequency of the received PA signal, as shown in Fig. 2.2(d).

9

Figure 2.2 Representative PA signals in the time and frequency domains. The laser spot size was 3 mm,
and the distance from the transducer surface to illumination spot was 5.6 cm. (a) Representative timedomain PA signal with zero flow speed, where the signal modulation is induced by the Ronchi ruling. (b)
Close-up of the PA signals at flow speeds of v1  0.63 m/s and v2  0.16 m/s. (c) Representative PA signal
spectrum at flow speed v1  0.63 m/s with a central frequency at 29.8 MHz. (d) Close-up of the frequency
spectra at flow speeds v1  0.63 m/s and v2  0.16 m/s.

In the first experiment, with the tube immersed in water, the flow speed of the ink solution was
varied from 0.020 m/s to 1.4 m/s. The four methods introduced above were used to calculate the
flow speeds. As shown in Figure 2.3, the measurements from all four methods agree well with the
preset speeds. The root-mean-square-errors (RMSE) of the four methods were 0.089 m/s, 0.095m/s,
0.10 m/s, and 0.057 m/s, respectively.

10

Figure 2.3 Flow speed measurements in a clear medium, based on four different methods. Solid lines: y  x
. (a) Flow speed measurement based on central frequency shift, with RMSE  0.089 m/s. (b) Flow speed
measurement based on arrival time shift, with RMSE  0.095 m/s. (c) Flow speed measurement based on
phase change versus frequency, with RMSE  0.10 m/s. (d) Flow speed measurement based on temporal
scaling, with RMSE  0.057 m/s.

In addition to the clear medium, PA flow measurements were also demonstrated in an intralipid
scattering medium. The intralipid solution above the tube surface was ~3 mm thick. The flow
speed was varied from 0.13 m/s to 0.63 m/s. The temporal scaling method and the central
frequency shift method were used for flow speed quantification, as shown in Figure. 2.4.
Compared with the measurements in the clear medium, the measured flow speeds in the scattering
medium had greater errors for both methods. For the time domain method, optical scattering
reduced the signal-to-noise ratio (SNR), which resulted in a greater error in the temporal scaling
measurement (RMSE: 0.066 m/s). For the frequency domain method, in addition to the reduced

11

SNR, the scattering also degraded the PA signal modulation depth, thereby increasing the difficulty
in measuring the central frequency (RMSE: 0.12 m/s).

Figure 2.4 Photoacoustic flow measurement in a 0.1% intralipid solution. (a) PA signal in the time domain.
(b) Flow speed measurements based on the central frequency shift method and temporal scaling method,
with RMSE  0.12 m/s and 0.066 m/s, respectively. Solid line: y  x .

Based on the translation and scaling properties of the Fourier transformation, the time shift in the
time domain is equivalent to the phase shift in the frequency domain, and scaling in the time
domain is equivalent to scaling in the frequency domain. Nevertheless, superior to the other three
methods, the central frequency shift method can sense the absolute flow speed instead of a relative
flow speed. Furthermore, the central frequency shift method does not assume uniform flow and
homogeneous acoustic property along the sound path between the laser spot and the transducer
surface. Instead, it requires only uniformity within the illumination spot, which is much easier to
satisfy in practice.
It should be noted that the proposed method assumes a uniform flow speed over the depth direction
of the tube that the laser can penetrate. However, this is not true for laminar flow, where the center
of the tube has the fastest flow. For the absorption coefficient of the ink solution, the 1/e
12

penetration depth of the light was approximately 8.3 mm, larger than the tube diameter. Therefore,
the measured flow speed was an average of the actual flow distribution.
The modulated light illumination provides a central frequency for the received PA signal, which
can help quantify the absolute flow speed. It transforms the otherwise wideband PA signal into a
narrowband signal. Without the light modulation, the wideband spectrum would be compressed or
stretched as well, depending on the flow direction. The scaling factor can also be used to estimate
flow; however, it can detect only relative flow speeds.
In the central frequency shift method, the maximum measurable flow speed is limited by the
frequency response of the transducer and SNR. Assuming the maximum frequency response of the
transducer is ~105 MHz, the maximum measurable flow speed is ~ 3700 m/s (flow is towards the
transducer), using Equation (2.2). Increasing the bandwidth of the transducer can increase the
maximum measurable flow speed. However, since the acoustic signal is attenuated more at higher
frequencies, higher frequency components have lower SNR, which will limit the maximum
measurable flow speed.
The minimum measurable flow speed, which is the velocity sensitivity of the system, is limited by
the signal length and SNR. Increasing the cycle number of the Ronchi ruling can improve the
frequency resolution, and thus decrease the minimum measureable flow speed. In addition, zeropadding can be used in the Fourier transformation to improve flow sensitivity. While zero-padding
cannot actually improve the frequency resolution, it can smooth the frequency spectrum and thus
improve the accuracy of locating the central frequency.23 If the noise is spectrally white, the
minimum measurable flow speed can be derived from the Cramér–Rao lower bound, which gives
an estimation accuracy of the central frequency as 24,25
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3 f s2
,
  2
 N(N 2 - 1)SNR

(2.8)

vmin  2 f va / f 0 ,

(2.9)

2
f

where  f is the standard deviation of the central frequency computed from the measured PA
spectrum, f s

is the sampling frequency, N is the number of sampling points, f 0 is the

modulation frequency, va is the speed of sound within the medium, and SNR  A2 2 n2 ( A is
amplitude of the signal and  n2 is the variance of the noise). In our experiment, given

SNR  10000 , N  10 4 , and f s  2.5 GHz, we get vmin  0.014 m/s.
In conclusion, we have proposed a flow speed measurement method based on the photoacoustic
Doppler effect in a homogeneous medium. Unlike the back-scattering based Doppler method, our
method does not require heterogeneity of the flowing medium on the scale of the spatial resolution.
As long as the medium is optically absorptive at a certain wavelength, such as pure water in the
infrared region, its flow speed can be measured based on the photoacoustic Doppler effect.
Although we emphasized the central frequency shift method, the other three methods can also be
utilized for relative flow speed calculation. While the current experimental setup is more suitable
for fast flow (>2.0 cm/s) measurement, the slow flow measurement capability can be improved,
for example, by increasing the modulation frequency.
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2.2 In Vivo Optically Encoded Photoacoustic Flowmetry
2.2.1 Background
Blood flow is an important physiological parameter and can be used to identify abnormal cell
activities, such as hypermetabolism in cancers28. Major non-invasive blood flow measurement
techniques include Doppler ultrasound flowmetry12, laser Doppler velocimetry17, and Doppler
optical coherence tomography. All of these techniques rely on acoustic or optical scattering
contrasts from moving media. Based on optical absorption contrast, photoacoustic (PA)
microscopy has been recently applied to high-resolution blood flow imaging. In comparison to
other techniques, PA microscopy provides inherently background-free detection and speckle-free
imaging19. Several PA flow measurement techniques based on the PA Doppler effect have been
explored23,29,30, but it has been reported that the PA Doppler signal strength decreases as the
particle concentration increases30,31. Additionally, the axial resolution achieved by tone-burst
excitation with a continuous-wave (CW) laser was relatively low compared with the axial
resolution achieved by pulsed excitation. Unlike the previous methods based on the PA Doppler
effect, Sheinfeld et al. measured the flow speed based on PA detection of thermal clearance 32. This
method does not reply on the inhomogeneity of the absorbers in the flow, and thus can potentially
measure the flow speed of homogenous media. However, the method was unable to separate
thermal convection from conduction, leading to low accuracy for slow flow measurements.
Recently, ultrasound-encoded photoacoustic flowmetry has been demonstrated 26,33. Based on a
similar idea, we present here an in vivo optically encoded PA flowgraphy (OE-PAF) capable of
high-resolution flow speed measurement of a homogeneous medium. As a heating source, an
intensity-modulated CW laser—acting as a “writing” beam—generates temperature variations
15

within the flowing medium. A pulsed laser is used as a “reading” beam to generate PA waves,
which are detected by a confocally aligned ultrasonic transducer. Since PA signals are sensitive to
the local temperature, the heated area generates higher PA signal amplitudes than nearby regions.
By scanning the reading beam along the flow direction, we can acquire PA images of the flow that
has been photothermally encoded by the writing beam. This method offers three advantages. First,
the modulation of the heating beam can be changed to generate different patterns, i.e., we can
“write” different “barcodes” into the flow, allowing the heating pattern to be optimized for the best
contrast-to-noise ratio. Second, both the photothermal encoding and the PA detection employ
endogenous optical absorption contrasts; thus, OE-PAF is label-free. Third, since OE-PAF directly
measures the displacement of the encoded flowing medium, thermal diffusion does not directly
impact the measurement. Therefore we do not need to calibrate the thermal diffusivity.

2.2.2 Methods
Mathematically, we assume that the temperature at the origin x  0 is modulated by a sinusoidal
heating beam, with a function H (t ) :
H (t )  H 0 sin(2 f 0t )

(2.10)

where H 0 is a constant, f 0 is the heating frequency, and t is the heating time. The PA
measurement is performed by linearly scanning the PA detection spot along the flow direction,
i.e., an imaged blood vessel of interest. Along the motor scanning direction, the temperature
change induced by the heating beam can be described as

T ( x, tb )  T0 ( x) sin{2 f 0 [tb  t0  x / (v f cos  )]}
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(2.11)

where T0 ( x ) is the amplitude of the temperature change, x is the distance from the heating point
to the PA measurement point, tb is a point on the B-scan (cross-sectional scan) time axis, 2 f 0t0
is the initial phase of the heating sinusoidal function ( t0 is a constant), v f is the flow speed, and

 is the angle between the flow velocity and motor scanning velocity vectors. The amplitude of
the detected PA signal, V , generated by the pulsed laser excitation, is proportional to the local
pressure rise, which can be described by 1
V ( x, tb )  [ 0   '0 T ( x, tb )] a ( x ) F ( x),

(2.12)

where  0 and  '0 are empirical constants related to the Grueneisen parameter, a ( x) is the optical
absorption coefficient, and F ( x ) is the optical fluence of the reading beam. Thus the time-variant
part of the PA signal detected by the transducer can be written as

V ( x, tb )   '1 ( x) a ( x) F ( x)sin{2 f 0 [tb  t0  x / (v f cos  )]}

(2.13)

where  '1 ( x)  T0 ( x) '0 . If the motor scans at a constant speed vm , equation (2.13) becomes

V ( x, tb )   '1 ( x)a ( x) F ( x)sin{2 f 0tb [1  vm / (v f cos  )]  2 f 0t0 }.

(2.14)

Equation (2.14) shows that, due to the blood flow and the motion of the transducer, the frequency
of the heating pattern has become [1  vm / (v f cos  )] f 0 ; thus the frequency shift from the heating
frequency is

f  

vm
f0 .
v f cos 

When vm  v f cos  , the PA signal becomes time-invariant:
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(2.15)

V ( x, tb )   '1 ( x)  a ( x) F ( x)sin(2 f0t0 ).

(2.16)

At position x , the PA signal amplitudes vary with the heating time t , which can be described as

V ( x, t )   '1 ( x) a ( x) F ( x) sin{2 f 0 [t  t0  x / (v f cos  )]}.

(2.17)

By performing cross-correlation between the time-variant PA signals at positions x1 and x2 , the
time delay t between the two signals can be calculated as follows:

t  arg max 

tmeas

0

t '

V ( x1 , t )V ( x2 , t  t ')dt

(2.18)

where t meas is the total measurement time. It can be seen that t is related to the flow speed as
well as the motor scanning speed, a relationship which can be expressed as

t 

x
x

v f cos  vm

(2.19)

where x  x2  x1 . If vm  v f cos  , or if we assume signals in the same B-scan are acquired at
the same time point, then when   0 , Equation (2.19) can be reduced to

vf 

x
t

(2.20)

2.2.3 Results
Figure 2.5(a) is a schematic of the experimental setup. A second-generation optical-resolution
photoacoustic microscopy system (OR-PAM)34 imaged the heat propagation. A pulsed laser beam
(532 nm) with a spot size of ~2 µm was focused onto the sample. The generated PA signals were
detected by an ultrasonic transducer with a central frequency of 50 MHz. To achieve high
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sensitivity, the ultrasound focus was coaxially and confocally aligned with the optical focus. The
B-scan rate was 8.3 Hz over a transverse range of 3 mm with 1600 A-lines. An intensity-modulated
CW laser light (532 nm wavelength; MLL-III-532, General Optoelectronic) with a spot size of
~0.4 mm heated the flow medium to generate temperature variation. The CW laser (100 mW) was
intensity-modulated at 0.5 Hz. The maximum distance between the heating and detection beam
was 3 mm, jointly limited by thermal diffusion, signal-to-noise ratio, and scanning range of the
PAM system used in the experiment. The minimum distance between the two beams was zero
when the centers of the two beam spots coincide. A tube (300 µm inner diameter, VWR®
International) filled with red ink solution was connected to a syringe. Flow speeds were set by a
syringe pump (BSP-M99, Braintree Scientific Inc.). Figure 2.5(b) is a schematic of an OR-PAM
scan for thermal flow measurement in a tube.

Figure 2.5 Schematic of optically encoded photoacoustic (PA) flowgraphy. (a) Schematic of secondgeneration OR-PAM system. BS, beam splitter; CCD, charge-coupled device; ConL, condenser lens;
CorL, correction lens; CW, continuous wave; PD, photodiode; ; RAP, right-angle prism; RhP, rhomboid
prism; SO, silicone oil; US, ultrasonic transducer; . (b) Schematic of OR-PAM scan for thermal flow
measurement in a tube.

As shown in Figure 2.6(a), the PA amplitudes from a tube image without heating were relatively
evenly distributed. Figure 2.6(b) shows space-time PA images acquired with heating on at three
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different flow speeds. The images in Figure 2.6(b) were obtained after subtracting the signals
averaged over the total measurement time. To increase the signal-to-noise ratio (SNR), the PA
images were averaged over 8 heating cycles. From Figure 2.6(b), it can be seen that the PA signals
were modulated by a sinusoidal wave both at the scanning axis (denoted by x ) and the heating
time axis (denoted by t ), as indicated by Equation (2.14) and Equation (2.17). Along the heating
time axis of the thermal pattern, the slope of the pattern, t / x , is the inverse of the flow speed,

1/ v f , as indicated by Equation (2.20). Thus it can be inferred that the slope was steeper for slower
flow speeds, and vice versa.

Figure 2.6 PA flow images of ink solution in a tube with a modulated heating frequency of 0.5 Hz. (a)
Maximum-amplitude projection (MAP) image of a silicone tube filled with red ink solution. Dashed line:
B-scan range. (b) Representative space-time images of a tube along the dashed line in (a) at different flow
speeds.

During heating, the maximum PA amplitude was 10.8% greater than the average PA amplitude,
corresponding to a 2.2 ºC temperature rise (room temperature 20 °C) 1. During the measurement,
the flow speeds were varied from 0.23 mm/s to 11.00 mm/s. The measured flow speeds were
shown in Figure 2.7. The straight line is a linear fit of the measurement points with a fitting
equation of y  kx . The coefficient k was found to be 0.998. The measurement errors were
estimated using the normalized RMSD, which was 2.0%
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.

Figure 2.7 Measured flow speeds based on optically encoded PA flowgraphy in a silicone tube. Modulated
heating frequency: 0.5 Hz. Error bars represent standard errors. N = 10 for each flow speed.

In vivo blood flow measurement was conducted in a nude mouse ear. The heating frequency was
0.5 Hz. The signals were averaged over 16 heating cycles to increase the SNR. Figure 2.8(a) shows
a MAP image of a mouse ear. The diameter of the vessel of interest is about 100 µm. The motor
scanned from A to B. We used an arbitrary-trajectory scanning technique 35, so that B-scans could
follow the paths of curved blood vessels. The heating spot was located at position B. The spacetime PA image of the heating pattern is shown in Figure 2.8(b). The image was obtained after the
signals averaged over the total measurement time were subtracted. By comparing the signals
between position A and position B (marked by the dashed line), we calculated the time delay, from
which we determined the flow direction as from position B to position A. Then using Equation
(2.20), the flow speed in the mouse ear was calculated to be 0.90 mm/s. During heating, the
maximum PA amplitude was 6.6% greater than the average PA amplitude, corresponding to a
temperature rise of 2.5 ºC (a body temperature of 37 °C was assumed) 1. In a second in vivo
experiment, the dynamic change in the PA amplitude from the mouse ear vessels was imaged with
0.1 Hz heating. The area near the heating spot shows stronger PA amplitude during the heating
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duty cycle, verifying the thermal effect. The 2D imaging frame rate was 1 Hz over a 0.8  1.6 mm2
area, using a MEMS-PAM system36. All the animal experimental procedures were in conformance
with the laboratory animal protocol approved by Washington University in St. Louis.

Figure 2.8 In vivo flow measurement in a mouse ear with a modulated heating frequency of 0.5 Hz. (a) PA
image of vessels in a mouse ear. A, starting point for B-scan following the curvature of the vessel. B, ending
point of B-scan. Dashed line, B-scan range. (b) Space-time image along the dashed line in (a). (c) PA signal
change with time at point A and B.

To achieve repeating heating patterns with sufficient contrast-to-noise ratio, before the next
heating cycle, the heating pattern “written” in the previous cycle has to flow fast enough to get out
of the original heating spot. i.e., (v f cos  )  T  d , where T is the heating period and d is the
heating spot size. Given d  0.4 mm, T  2 s, and   0 , then v f  0.2 mm/s. From the equation,
it can be seen that decreasing the heating frequency and minimizing the heating spot size could
reduce the minimum measureable flow speed. Increasing the sensitivity of the PA system and
improving the contrast-to-noise ratio of the heating pattern (e.g., by increasing the heating power)
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could make the minimum measurable flow speed closer to the theoretical value. Contrariwise,
thermal diffusion could smooth out the heating pattern and decrease the contrast-to-noise ratio,
which would increase the minimum measurable flow speed.
From Equation (2.19), it can be inferred that the time delay t should be positive, i.e.,
t 

x
x

 0 , thus v f  vm / cos  . For our current experimental setup, vm  25 mm/s,
v f cos  vm

  0 , and thus the maximum measurable flow speed is 25 mm/s.
Though the current experiment setup used a CW laser to generate the sinusoidal thermal pattern,
the heating beam could also come from a pulsed laser, and different heating functions could be
applied as long as adequate contrast-to-noise ratio is achieved. Note that the proposed method is
sensitive to all thermal carriers and can be applied to homogeneous media. With the current setup,
the heating beam and detection beam are on the opposite sides of the sample, imposing limitations
on the thickness and absorbance of the sample. In the future, an improved setup with the two beams
at the same side could be utilized.
In summary, we present an optically encoded photoacoustic flowgraphy in vivo. In this method,
the flow was encoded by a thermal pattern. Then, we “read” the pattern using an optical-resolution
photoacoustic microscopy system. The flow speed was calculated from PA images by crosscorrelation. The proposed technique enabled high-resolution measurement of flow speed as slow
as 0.23 mm/s in phantoms and in vivo measurement of blood flow in a mouse ear.
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2.3 Conclusions
For homogenous flow measurement, we encoded the flow with structured illumination and with a
thermal pattern to create a “virtual” contrast for PA flowmetry. We “read” the grating pattern and
the thermal pattern with an ultrasonic transducer. The calculated difference between the original
pattern we input and the pattern “read” by the transducer was generated by the flowing medium.
These methods do not require the presence of absorbers with sizes larger than the system
resolution. Although demonstrated in vivo in the mouse ear, the applications of the proposed
methosd are limited to shallow flow media due to the limited depth that can be reached by the
structured illumination or the thermal pattern induced by the CW laser.

24

Chapter 3 Photoacoustic Microscopy of Cells
with Endogenous Contrasts
Photoacoustic microscopy has been widely used for structural and functional imaging based on
the absorption contrast of red blood cells. In this chapter, we demonstrate the feasibility of labelfree imaging of one type of white blood cells, macrophages, which play an important role in the
immune system. We also extend the previous study of cell nuclei imaging of thin samples to 3D
whole organ imaging with subcellcular resolution. The cell nuclei imaging is based on the joint
work of Terence Wong and Chi Zhang.

3.1 Label-free Photoacoustic Imaging of Macrophages
3.1.1 Background
Macrophages play key roles in host defense, removing cellular debris generated during tissue
remodeling, and rapidly and efficiently clearing cells that have undergone apoptosis
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. Some

macrophages, called wandering macrophages, travel throughout blood and lymph streams to reach
infectious sites and kill microbes. Others are stationed at critical locations in the body, such as the
lymph nodes, bone marrow, spleen, and liver. In diseased tissues, the number of macrophages can
increase profoundly. Thus the ability to quantitatively monitor macrophages in lymph flow and to
image tissue macrophages (their density, flux rates, function, and subtypes) is important in the
diagnosis and treatment of cancer, atherosclerosis, and myocardial infarction. The optical
absorption of white blood cells (including macrophages, monocytes, and lymphocytes) is much
weaker than that of red blood cells, thus they are often regarded as negative contrast for
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photoacoustic imaging. While numerous photoacoustic imaging studies are based on the
absorption of hemoglobin19, and some studies focus on the imaging of white blood cells
(macrophages) with exogenous biomarkers, label-free photoacoustic imaging based on the
intrinsic absorption of macrophages has not been performed. It should be noted that although a
spectrophotometer can measure the optical absorption spectrum of a solution easily, it cannot
provide an accurate spectrum of intact cells. Here, using an optical resolution transmission-mode
photoacoustic system, we explored the intrinsic absorption of macrophages over the visible
spectrum range, and monitored the flow of macrophages in a phantom tube. With multiple
wavelengths, it is possible to differentiate macrophages from red blood cells in the blood stream,
or to spectrally identify them in the lymph flow, which can be used for macrophage monitoring
and cell counting in vivo. In diseased tissues, photoacoustic imaging of the distribution and density
of macrophages may provide helpful information to physicians for the diagnosis and therapy of
diseases.

3.1.2 Methods
Mouse macrophage RAW264.7 cells from the American Type Culture Collection were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum at 37 °C in a
5% CO2 air atmosphere. For PA imaging, we placed macrophages suspended in phosphate
buffered saline solution (~ 20 μL) onto a microscopic glass slide. To study flowing macrophages,
the macrophages suspended in the phosphate buffered saline solution were circulated by a syringe
pump in a silicone tube (300 um ID, VWR Inc.).
An integrated diode-pumped Q-switched laser and optical parametric oscillator system (NT 242SH, Ekspla) generated laser pulses (5 ns pulse width, 1 kHz repetition rate) with a tunable
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wavelength range from 210 to 2600 nm. The laser pulses were sequentially filtered by an iris (2
mm aperture), focused by a condenser lens, filtered by a 50 µm pinhole, and focused again by an
objective. The objective for visible light (460715, Zeiss) had a 0.6 numerical aperture (NA). The
focused laser pulse generated a spatially and temporally abrupt temperature rise, which generated
photoacoustic waves through thermoelastic expansion. The photoacoustic waves were coupled by
water and detected by a focused ultrasonic transducer with a 40 MHz center frequency (80%
bandwidth, 0.50 NA). Then they were amplified, digitized at 1GS/s (PCI 5152, National
Instruments), and finally recorded by a computer. A 2D maximum amplitude project image was
formed by raster scanning the sample along the x and y directions, as shown in Figure 3.1.

Figure 3.1 Transmission-mode PAM for multispectral imaging of macrophages.

For the spectrum measurement, the wavelength was tuned from 405 nm to 610 nm with a 5 nm
step size. At every wavelength, the amplitudes of photoacoustic signals from 10 4 A-lines of
macrophages on a glass slide were recorded and averaged. The standard error was calculated for
each point, as indicated in Figure 3.2. To monitor flowing macrophages, m-mode at 1 kHz was
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used to capture the motion of the macrophages. A 2D image of macrophages in a tube was formed
by converting the time axis to the distance axis.

3.1.3 Results
The normalized absorption spectrum of macrophages was calculated (Figure 3.2(a)) in the visible
range, showing that the absorption peak is around 420 nm. We also compared the spectrum of
macrophages with that of hemoglobin, which is a predominant optical absorber in the visible range
(Figure 3.2(b)). It can be seen that the spectra of macrophages, oxy-hemoglobin, and deoxyhemoglobin have very distinctive spectrum peaks, indicating the potential of photoacoustics to
spectrally distinguish them in diseased tissue or in lymph flow. Individual macrophages fixed on
a microscopic glass slide can be clearly visualized as a circular shape by the transmission-mode
photoacoustic system, as shown in Figure 3.3. Flowing macrophages were imaged using M-mode
as shown in Fig. 3.4. The cross-sections of two flowing macrophages can be observed in the tube
at 1 kHz imaging rate.

Figure 3.2 Photoacoustic spectrum of live macrophages. (a) Normalized photoacoustic spectrum of
macrophages from 405 nm to 610 nm. (b) Normalized photoacoustic spectra of macrophages, oxyhemoglobin, and deoxy-hemoglobin. The spectra of oxy- and deoxy-hemoglobin are from the reference 38.
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Figure 3.3 PAM at 420 nm of macrophages fixed on a microscopic glass slide

Figure 3.4 Cross-sectional images of macrophages flowing in a silicone tube. The macrophages were
suspended in a phosphate buffered saline solution.

In conclusion, the absorption spectrum of macrophages was characterized using a transmissionmode photoacoustic microscope system. Based on the spectrum information, the macrophages
could be potentially spectrally differentiated from red blood cells because they have a distinctive
absorption spectrum from that of the deoxy- and oxy-hemoglobin. The imaging of flowing
macrophages also indicates the possibility of monitoring macrophages in the lymph flow in vivo,
which will be a value tool for clinical applications in the future.
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3.2 Label-free Microtomy-assisted Photoacoustic
Microscopy of Whole Organs
3.2.1 Background
Histologic analysis of tissue has been widely used in both preclinical and clinical settings because
it can provide information about the tissue down to the organelle level. To acquire histology images
of a thick sample (e.g., a whole organ from a mouse) requires sectioning of the sample before
imaging by optical microscopes. The registration of the images from different slices performed
after the imaging often leads to different levels of inaccuracy and distortion of the volumetric
image despite rectification efforts 39-44. Also, for histology imaging, the tissue needs to be stained
with H&E to image cell nuclei. In previous work, PAM has been used for UV imaging of cell
nuclei in thin tissue samples3,45. It has also been shown that PAM can provide histology-like
images at UV wavelengths. Here we demonstrate 3D label-free photoacoustic imaging of the cell
nuceli distribution in whole organs with subcellular resolution, enabled by a microtome.
We imaged formalin-fixed mouse brain tissue and mouse lungs embedded in paraffin with
microtomy-assisted photoacoustic microscopy (mPAM). In H&E staining, cell nuclei are
identified by the color difference between the cell nuclei and cell cytoplasm in the histology images
after staining. Similarly, in mPAM, because the cell nuclei absorbed much more strongly than the
cytoplasm at the UV wavelength, cell nuceli had much stronger signals than the cytoplasm. This
difference provided the photoacoustic contrast between cell nuclei and cytoplasm and enabled
histology-like photoacoustic images.
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3.2.2 Methods
Mouse brains and lungs were extracted from Swiss Webster mice (Hsd: ND4, Harlan Laboratories)
immediately after the animal was sacrificed. Then the organs were fixed in 10% neutral-buffered
formalin for several days before they were embedded in paraffin as block specimens for
photoacoustic imaging. All experimental animal procedures were carried out in conformity with
laboratory animal protocols approved by the Animal Studies Committee of Washington University
in St. Louis.
The mPAM system (Figure 3.5) is controlled by the user through a LabVIEW program. A central
controller with a real-time processor (400 MHz) and a reconfigurable field-programmable gate
array receives the parameter input from the LabVIEW program and sends out a corresponding
trigger to a Nd:YLF Q-switched UV laser (266 nm wavelength, 7 ns pulse width, QL266-010-O,
CrystaLaser,Inc) at a 10 kHz pulse repetition rate. The laser beam is expanded by a pair of lenses
and filtered by a pinhole. Then a custom-made water immersion UV objective lens with a NA of
0.16 focuses the laser beam onto the specimen. The lateral resolution defined by the optical focal
spot was measured to be 0.91 µm. As the specimen absorbs the UV light, the resulting
photoacoustic waves are detected by a custom-made ring-shaped ultrasonic transducer (42 MHz
central frequency, 76% bandwidth). A hole in the center of the ring-shaped transducer allows the
delivery of light directly to the specimen. The axial resolution of the system, determined by the
penetration depth of UV light, was around 20 µm.
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.
Figure 3.5 System schematic of microtomy-assisted PAM

The detected photoacoustic signals are then amplified and acquired by a data acquisition card.
Two-dimensional raster scanning is realized by a two-axis scanning stage, which is controlled and
synchronized with the laser by the central controller. After each imaging scan of the surface of the
specimen, a microtome blade controlled by the central controller automatically sections the surface
of the specimen while the specimen stays in the original position. The imaging and sectioning
processes repeat until the entire specimen is imaged. To generate the nuclear density map, we first
generated a nuclear image by Hessian filtering. Each nucleus in the image was reduced to one
pixel with unit amplitude, and the background was set to zero amplitude. Then each pixel of this
new image was replaced by the average of the 50 × 50 μm 2 surrounding area, creating a nuclear
density map where each pixel value equaled the relative nuclear density of the 50 × 50 μm 2
surrounding area. Next, we used mPAM to image a formalin-fixed unstained mouse brain
embedded in a paraffin block. The block was imaged on the surface and sectioned repeatedly and
re-imaged at 20 μm thickness by mPAM. The imaged volume of 3.0 mm by 3.8 mm by 2.0 mm,
which covers both the cerebrum and the cerebellum. A series of PA images were acquired at the
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block surface before sectioning, and a 3D volume was reconstructed without the need for image
registration.

3.2.3 Results
As shown in Figure 3.6, the reconstructed 3D photoacoustic image did not present distortion
artifacts or discontinuous structures, which are common problems in 3D histology. Figure 3.6(a)(b) show the volume at different angles, with coronal and sagittal views of the mouse brain. The
cell nuclei, extracted and enhanced by Hessian filtering, appear as bright dots in the images (Figure
3.6(c)).

Figure 3.6 Volumetric mPAM image of a fixed mouse brain specimen embedded in a paraffin block. (a)(b)
Individual cell nuclei are highlighted as bright dots and shown from different viewing angles. (c) A closeup view of the specimen shown in (b).

In addition to mouse brain sample imaging, a formalin-fixed mouse lung was embedded in paraffin
and imaged by mPAM. mPAM images of mouse lung sections at different layers of the specimen
show different alveoli structures (Figure 3.7). Similar to the mouse brain imaging, individual cell
nuclei can be extracted (bright dots). The imaged volume was 1.5 mm by 1.0 mm by 1.2 mm, with
61 sections and a 20 µm section thickness. These results demonstrate that mPAM can provide
histology-like imaging of whole organs with subcellular resolution.
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Figure 3.7 Volumetric mPAM image of a fixed mouse lung specimen embedded in a paraffin block. (a)-(c)
Mouse lung specimen at different layers, revealing various alveoli features and individual cell nuclei
distribution.

3.3 Conclusions
In this chapter, the imaging of macrophages demonstrates the potential of PAM to image weakly
absorbing endogenous proteins within the cytoplasm in the visible range. This method can
potentially be extended to other weakly-absorbing cell types. Moreover, with UV light, we
demonstrated automated three-dimensional cell nuclei imaging of whole organs with subcellular
resolution. When combined, the visible and UV light can potentially be used to excite any cell
types for PA imaging of the cytoplasm and nuclei without staining of the specimen.
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Chapter 4 Photoacoustic Neurovascular
Imaging and Therapy with Copper
Nanoparticles
Nanoparticles represent the largest class of contrast agents for molecular PA imaging8. Previously,
gold nanoparticles were the main research focus. Here, we apply more biocompatible and more
affordable copper nanoparticles to targeted imaging and therapy of angiogenesis. The copper
nanoparticles were synthesized and provided by Dr. Gregory Lanza’s lab. The work described in
this chapter was published in Theranostics46.

4.1 Background
As an important component of an expanding vascular network the neovasculature can be viewed
as a biomarker of inflammation associated with tumor aggressiveness or atherosclerotic plaque
progression. 47-49 To date, noninvasive imaging of angiogenesis has been essentially a preclinical
endeavor, although imaging candidates have reached the clinical testing level for MRI and nuclear
medicine. Nuclear medicine probes, although exquisitely specific for neovascular biosignatures,
such as the ανβ3-integrin, are not specific to angiogenesis, since this adhesion molecule is activated
on numerous cell types present in tumors or atherosclerotic lesions.

50-52

By comparison, MRI

paramagnetic nanoparticle agents are often vascular-constrained by size and very specific for
neoendothelial expression of ανβ3-integrin, but such agents have experienced other roadblocks in
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the clinic. 53 Photoacoustic molecular imaging offers noninvasive vascular-constrained detection
of angiogenic biomarkers with very high resolution imaging of the neovasculature.
Different imaging modalities have different characteristic resolution limits, with microscopic
images having the highest resolution for thin specimens. For biomedical instrumentation, ultrahigh spatial resolution MRI at 3.0T and high resolution CT provide in vivo blood vessel images
but with a poorer resolution, in the range of 200 to 500 μm, which is inadequate for discrete
neovessel imaging.

54-58

Photoacoustic (PA) imaging combines the advantages of ultrasound

imaging and optical imaging and offers high depth-to-resolution ratios at different spatial scales,
ranging from organelles to organs, 59 as well as unique and important physiological assessments,
such as differential circulating blood oxygenation levels.
Previous studies have confirmed that PA imaging’s utility can be markedly extended with
exogenous contrast agents. 60-62 In many instances, these contrast agents have been based on gold
cubes, spheres, or rods with particle sizes greater than the renal clearance threshold (<8 to 10 nm),
creating difficult translational challenges when proving long-term safety in man. Gold
nanobeacons (120-160 nm) were developed to achieve the large absorption cross-sections of
bigger solid gold particles by suspending a multitude of small gold nanoparticles (3-5 nm) in a
hydrophobic matrix encapsulated with phospholipid (160 nm). 63 Moreover, the optical absorption
wavelength of nanoparticles was tunable well into the NIR optical window, minimizing
endogenous absorption and maximizing PA imaging depth.
However, the pressure of healthcare economics has placed an emphasis on driving the costs of
imaging studies down, and we have thus sought lower cost biocompatible alternatives to gold. We
hypothesized that nanoparticles entrapping high densities of organically soluble small molecular
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weight copper complexes could provide an inexpensive and effective approach to neovascular
targeted PA imaging. The choice of copper as a cheaper, biocompatible alternative to gold was
independently supported by a recent report describing nontargeted crystalline copper sulfide
nanoparticles as PA contrast agents for deep tissue imaging at 1064 nm.
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In this research, a soft

noncrystalline ανβ3-targeted copper-oleate nanoparticle (ανβ3-CuNP) was developed and its PA
imaging signal with respect to blood and the previously reported gold nanobeacons was
characterized
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as a function of NIR wavelength and with varying nanoparticle concentrations.

The in vivo efficacy of ανβ3-CuNPs for high-resolution imaging of mouse neovasculature was
examined in a Matrigel™ model of angiogenesis. Furthermore, the theranostic antiangiogenic
potential of ανβ3-CuNPs incorporating a novel Sn 2 lipase-labile fumagillin prodrug (Fum-PD)
was also studied. 65

4.2 Material and Methods
Reagents

Unless otherwise listed, all solvents and reagents were purchased from Aldrich

Chemical Co. (St. Louis, MO) and used as received. Anhydrous chloroform and methanol were
purchased from Aldrich Chemical Co. Poly(styrene-b-acrylic acid) (PS-b-PAA) was purchased
from Polymer Source Inc. (Montreal, Canada). High purity egg yolk phosphatidylcholine was
purchased from Avanti Polar Lipids, Inc. Cholesterol and cooper oleate were purchased and used
as received from Aldrich Chemical Co. (St. Louis, MO). Sorbitan monolaurate was purchased
from Aldrich. Argon and nitrogen (Ultra High Purity: UHP, 99.99%) were used for storage of
materials. The Spectra/Por membrane (Cellulose MWCO: 20,000 Da) used for dialysis was
obtained from Spectrum Medical Industries, Inc. (Laguna Hills, CA).
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Preparation of Sn 2 lipase labile Fumagillin prodrug

Synthesis of the Sn 2 prodrug was

accomplished in two steps: 1) saponifying fumagillin dicyclohexylamine salt to fumagillol, and 2)
esterifying the product with 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC).
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Briefly, fumagillin dicyclohexylamine salt (NCI) in 1:1 methanol:water was treated with 35%
NaOH, stirred in an ice bath for 2 h, warmed to room temperature, treated with another equivalent
of 35% NaOH, and then stirred in an ice bath until the starting material was not detected by TLC
(∼4 h). After evaporating the methanol and solubilizing in ethyl acetate, the mixture was extracted
with 5% citric acid, brine, bicarbonate, and brine again, then dried with MgSO 4 and concentrated
in vacuo. The crude product was purified with activated charcoal in acetonitrile and then filtered
through a celite pad. (Yield: a colorless solid, 59 mg (70%). 1H NMR (CD 3OD): δ 5.20 (t, 1H),
4.3 (m, 1H), 3.42 (m, 1H), 3.38 (s, 3H), 2.88 (d, 1H), 2.63 (t, 1H), 2.51 (d, 1H), 2.1–2.3 (m, 2H),
2.2 (m, 1H), 1.89 (d, 1H), 1.7–1.9 (m, 2H), 1.8 (d, 3H), 1.7 (d, 3H), 1.17 (s, 3H), 0.96 (m, 1H).
HR-MS found: MH+ (283.3).
A solution of C16-09:0 (COOH) PC 1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine,
followed by 4-dimethylaminopyridine (DMAP) and N, N'-dicyclohexyl-carbodiimide (DCC), was
added to fumagillol in dry dichloromethane. The reaction mixture was stirred overnight at ambient
temperature then passed over a short pad of silica gel using EtOAc/n-hexane. The filtered solvent
was removed in vacuo, and the oil residue was purified by column chromatography on SiO 2 using
EtOAc/n-hexane for elution to yield the fumagillin prodrug (Fum-PD) compound as a pale
yellowish solid (yield: 54%). 1H NMR (CDCl3): δ 0.88 (t, 3H), 1.22–1.37 (m, 37H), 1.58–1.96
(m, 20H), 2.26–2.60 (m, 7H), 3.40 (m, 12H), 3.48 (m, 3H), 3.86–4.00 (m, 4H), 4.10–4.37 (m, 5H),
5.21 (m, 1H). HR-MS found: 930.6 (MH+).

38

Preparation of copper nanoparticles

Copper-oleate (260 mg) dissolved in toluene was

suspended in almond oil (4 ml), gently vortexed to homogeneity, and filtered through a small bed
of cotton. The solvent was evaporated under reduced pressure at 45°C, leaving a mixture
containing 65 mg of copper oleate per ml. The surfactant co-mixture included high-purity egg yolk
phosphatidylcholine (91.9 mol%), cholesterol (8 mol%), and α νβ3-peptidomimetic antagonist
conjugated to PEG2000-phosphatidylethanolamine (0.1 mol%; Kereos, St. Louis, MO, USA).
Therapeutic ανβ3-CuNPs incorporated the Sn 2 lipase labile fumagillin prodrug (2.28 mol%) at the
equimolar expense of phosphatidylcholine. The surfactant co-mixtures were dissolved in
chloroform, evaporated under reduced pressure, dried in a 40°C vacuum oven overnight, and
dispersed into water by probe sonication. This suspension was combined with the copper oleatealmond oil mixture (20% v/v), distilled deionized water (77.3% w/v), and glycerin (1.7%, w/v)
and continuously processed at 20,000 psi for 4 min with an S110 Microfluidics emulsifier
(Microfluidics, Newton, MA, USA) at 4°C. The copper nanoparticles (CuNPs) were dialyzed
against water using a 20-kDa MWCO cellulose membrane for a prolonged period of time and then
passed through a 0.45 µm Acrodisc syringe filter (Pall Life Sciences, East Hills, NY, USA). To
inhibit lipid oxidation, the CuNPs were stored under an argon atmosphere, typically at 4°C (Figure
4.1).
The nominal hydrodynamic diameter (Dh) of the αvβ3-CuNPs and the fumagillin prodrug CuNPs
was determined by dynamic light scattering (DLS) measurements (Brookhaven ZetaPlus,
Brookhaven Instruments Corporation) in aqueous solution, were typically 190 nm ± 15 nm (std
error), with a polydispersity of 0.09 ± 0.01, and a zeta potential of -23 ± 06 mV. Incorporation of
the prodrug at 2.28 mol% (~0.5 mM) within the surfactant co-mixture had negligible impact on
particle sizes.
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The ανβ3-integrin antagonist was a quinalone nonpeptide developed by Lantheus Medical Imaging
(Billerica, MA, USA) and synthesized by Kereos (U.S. Patent 6,511,648 and related patents). The
vitronectin antagonist was reported and characterized as the
cyan 5.5 homologue TA145.
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111

In-DOTA conjugate RP478 and

The homing specificity of the ligand was demonstrated and

characterized with Matrigel plug implanted in Rag1tm1Mom Tg (Tie-2-lacZ)182-Sato and C57Bl/6
mice. 60

Figure 4.1 Synthesis and physiochemical characterization of CuNPs. (a) schematic of the concept of CuNPs
with fumagillin prodrug; (b) hydrodynamic particle size distribution from DLS. The nominal hydrodynamic
diameters of αvβ3-CuNPs and fumagillin prodrug CuNPs were typically 190 nm ± 15 nm, (c). Anhydrous
state atomic force microscopy (AFM) image of CuNPs (drop-deposited on glass) Average height: 80 nm ±
12 nm. (d). EDX spectrum generated from the SEM image
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The reference gold nanobeacons (GNBs) used in this study were prepared and characterized as
previously described. 60 The GNBs were in a 20 vol% suspension with a nominal particle size of
160 nm, containing 6120 gold-oleate particles (3-5 nm)/nanobeacon, with a gold content of 1080
µg/g.
Matrigel™ plug mouse model of angiogenesis

All animal studies were conducted in

accordance with protocols approved by the Animal Care and Use Committee of Washington
University Medical School.
Athymic nude-mice (Harlan Labs, Indianapolis, IN) with body weights ranging from 23 to 27 g
were obtained. Anesthesia was induceod by ketamine (100 mg/ml) and xylazine (20 mg/ml), which
were maintained with 0.5% to 1% isoflurane in oxygen, with ventilator support and supplemental
temperature support. Matrigel (0.5 ml, BI, Biosciences, San Jose, CA, USA) enriched with
fibroblast growth factor-2 (500 nm/ml; Sigma-Aldrich, St. Louis, MO, USA) and heparin was
implanted subcutaneously along the mouse flank. The nude mice (n = 12) were randomly
distributed into four groups to test (1) the efficacy of ανβ3-CuNPs for PA molecular imaging of
angiogenesis in vivo and (2) the efficacy of ανβ3-CuNPs with Fum-PD as a theranostic agent. For
the first test, three groups were compared on day 18 using PA imaging: (1) α νβ3-CuNPs without
Fum-PD (integrin targeted, n=3); (2) nontargeted CuNPs (nonspecific entrapment, n=3) and (3)
ανβ3-almond oil nanoparticle (NP) followed after 10 min by α νβ3-CuNPs without Fum-PD (specific
competition, n=3). To address the second question within the same experimental design, (4) α νβ3CuNPs with Fum-PD were administered on days 11 and 15, following Matrigel implantation, and
the effect on angiogenesis was assessed on day 18 with α νβ3-CuNPs without Fum-PD (n=3). All
treatments were injected via tail vein at 2 μl/g body weight of the 20 vol% nanoparticle
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suspensions. For each animal dynamic PA imaging was performed before injection (baseline, 0
min) and then repeated every 30 min over 270 minutes post-injection.

Figure 4.2 System schematic of a reflection-mode dark-field illumination PA system
Photoacoustic imaging

A reflection-mode PA imaging system (Figure 4.2) using dark-field

ring-shaped illumination 67 was pumped by a Q-switched Nd:YAG (LS-2137; Lotis TII) laser with
<15-ns pulse duration and a 10-Hz pulse repetition rate. The light energy on the sample surface
was controlled to conform to the American National Standards Institute (ANSI) standard for
maximum permissible exposure. A 10 MHz central frequency, spherically focused (2.54 cm focus
length, 1.91 cm diameter active area element, and 68% nominal bandwidth (One way -6 dB
bandwidth is ~96%) ultrasonic transducer (V315; Panametrics-NDT, Waltham, MA, USA)
acquired the generated PA signals. The signal was amplified by a low-noise amplifier (5072PR;
Panametrics-NDT), and recorded using a digital oscilloscope (TDS 5054; Tektronix, Beaverton,
OR, USA) with 50-MHz sampling. PA signal fluctuations due to pulse-to-pulse energy variation
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were compensated for by signals from a photodiode (DET110; Thorlabs, Newton, NJ, USA),
which sampled the energy of each laser pulse.
Prior to in vivo imaging, two preliminary experiments were performed. In preliminary experiment
1, individual samples of CuNPs (20 vol%) and bovine blood (hct. ~45%) were placed into
individual transparent plastic tubes (ID, 510 µm) and imaged by the PA system at 767 nm. The Aline signals from these two tubes are presented in Figure 4.3 as superimposed waveforms.
In preliminary experiment 2, the transparent Tygon tubes (ID, 510 µm) were filled with CuNPs
(20 vol %), GNBs (20 vol%), and whole bovine blood (hct. ~45%). They were imaged at varying
wavelengths between 730 nm and 830 nm. As an extension of this experiment, CuNPs were
serially diluted from 6.0 µM to 0.17 µM and imaged at 750 nm, 760 nm, 770 nm, 780 nm, and 790
nm. In each experiment, the maximum amplitudes of the A-line signals (n=5) at each wavelength
were averaged.
Finally, in vivo imaging of angiogenesis in the Matrigel Plug model was performed. A linear
translation stage (XY-6060; Danaher Motion, Rad ford, VA, USA) was used for raster scanning
to obtain 3-D PA data. A computer controlled the stage and synchronized it to the data acquisition.
To shorten the data acquisition time, a continuous scan was used without signal averaging. Typical
scanning values are as follows: voxel dimensions, 0.1 × 0.2 mm; laser pulse repetition rate, 10 Hz;
acquisition time, ~20 min.
In vivo imaging was performed using ventilated anesthetized mice with shaved flanks, constantly
warmed to 37°C by a heating block and positioned immediately beneath the transparent clear
membrane. PA imaging was performed at 767 nm, as previously used for GNB in vivo. 60 Similarly,
the vessel-integrated PA amplitude, calculated by integrating the enveloped PA signal amplitude
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over the blood vessel region , was used to quantify the degree of angiogenesis. The vesselintegrated PA amplitude was normalized to that of the pretreatment level during the analysis.
Statistical Analysis Data were analyzed using analysis of variance (GraphPad Prism Ver. 6.03)
(p < 0.05). Data are presented as the mean ± standard error of the mean unless otherwise stated.

4.3 Results
Given the inherently strong PA signal of hemoglobin, the efficacy of PA contrast agents for
targeted molecular imaging of neovascular integrin expression is dependent on the strength and
differentiation of its signal from the blood background. The PA signal of CuNPs (20 vol%) was
compared with whole bovine blood (45% hct.) at 767 nm. As seen in Figure 4.3, the time-aligned
PA signal of the copper NP emulsion was markedly greater than that of the bovine blood at 767.
The peak-to-peak signal of the CuNPs (2.3 a.u.) was 4-fold greater than that of blood (0.58 a.u.)
at 767 nm, suggesting that the PA signal of neovascular bound CuNPs could be readily detectable
in vivo.

44

Figure 4.3 Overlay of PA signals from CuNPs and blood. CuNPs(20 vol%) and blood samples (whole
bovine blood, hct. 45%;)were placed into transparent TygonTM tubes (ID = 510 µm) and imaged by the
PA system at 767 nm. The peak-to-peak PA signal from the CuNPs was 4 times greater than that of the
blood at 767 nm.

GNBs have been previously shown to produce strong PA contrast in vivo when applied to sentinel
lymph node imaging or when targeted to neovasculature in vivo.

60,63,68,69

The PA signal

enhancement of CuNPs relative to blood (45% hct.) was compared to the signal of GNBs relative
to blood across a NIR frequency range of 730 nm to 830 nm (Figure 4.4) on an equal nanoparticle
number basis. Over almost the entire spectrum, the CuNPs signal strength relative to blood was
around 5-fold greater with a noticeable decline beyond 820 nm. In general, the PA ratios of GNBs
and CuNPs were very similar except between 760 nm and 790 nm, with the greatest divergence
between GNBs and CuNPs at 770 nm, at which point the gold contrast result was nearly twice that
of copper. GNB particles experienced the same declining results as CuNPs from 800 nm and
beyond.

Figure 4.4 Equal-nanoparticle-based ratio of peak-to-peak PA signal amplitudes from previously reported
gold nanobeacons (20 vol%) and CuNPs (20 vol%) to those of whole bovine blood (hct. 45%) over the 730
– 830 nm range. Over the whole spectrum, PA signals of CuNPs were markedly greater than those of the
blood. In general, the PA ratios of GNBs and CuNPs relative to blood were similar.
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The concentration dependence of CuNPs’ signals as a function of frequency was examined. CuNPs
were serially titrated from 6.0 µM to 0.17 µM and studied at NIR wavelengths between 750 nm
and 790 nm (Figure 4.5(a)). PA amplitude decreased with reductions in CuNP concentration level,
but the magnitude of signal diminishment was generally less than the percent change in CuNP
level. This was particularly notable for the higher concentrations, between 6.0 µM and 1.5 µM.
The magnitude of the CuNP’s PA signal was greatest at 750 nm and 760 nm. At higher
wavelengths, the magnitude of the CuNP signal trended lower, with the greatest contrast loss seen
at the lower CuNP concentrations. It can be calculated from the extinction coefficient spectrum
shown in Figure 4.5(b) that the extinction coefficient of CuNPs at 700 nm was 1.3 times as strong
as that at around 770 nm. However, the laser energy at 767 nm (the peak of laser energy) is an
order of magnitude stronger than that at 700 nm. Therefore, neovascular imaging signal peaks
around 767 nm.

Figure 4.5 Photoacoustic spectrum characterization of copper nanoparticles. (a) PA signals from copper
nanoparticles (20 vol%) in a transparent Tygon tube filled with serially diluted copper nanoparticles (0.17
µM, 0.38 µM, 0.75 µM, 1.5 µM, 3.0 µM, 6.0 µM) at laser wavelengths from 750 nm to 790 nm, with 10
nm step size. A nonlinear relationship between the PA amplitude and CuNP concentration was observed.
(b)The extinction coefficient spectrum of the CuNPs (20 vol%) at laser wavelengths from 500 nm to 800
nm.
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To provide robust assessment of PA signal enhancement due to the CuNPs, in vivo neovascular
imaging was studied in the Matrigel plug model in mice. Mice implanted with Matrigel™ 18 days
previously received either ανβ3-CuNPs, nontargeted CuNPs, or ανβ3-CuNP preceded by 10 minutes
with a competitive dose ανβ3-oil only NPs (1:1). As seen in Figure 4.6, at 0 min, forming neovessels
were observed by the inherent PA contrast imparted by erythrocyte hemoglobin. The magnitude
of the signal varied among animals with the extent of neovascular proliferation. Following α νβ3CuNP injection, the magnitude of the PA signal in these immature tubules clearly increased, and
numerous incomplete vascular sprouts appeared, as we have previously reported for GNBs. 60 The
formation of the neovessel shoots depicted an early evolution stage of a dense and irregular
microvasculature. In contradistinction to the animals receiving ανβ3-CuNPs, those given
nontargeted-CuNPs had very little increase in the vessel-integrated PA amplitude. As shown, a
minimal passive accumulation of the CuNPs in the forming bridges and sprouts combined with a
modest amount of blood pool enhancement relative to the neovessel tubules at 0 min. We have
previously reported that blood pool enhancement for GNBs in the intact microvasculature
surrounding the Matrigel implant was negligible,

60

but within the plug, the slow moving blood

may be associated with very slow washout. In the competition group at 170 min, very little change
in the PA signal from the forming vascular tubules or sprouts was observed. In this group, the
pretreatment binding of the ανβ3-oil NPs appeared to have blocked most of the receptors for the
ανβ3-CuNP and even precluded significant passive accumulation.
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Figure 4.6 In vivo PA images of the Matrigel plug area implanted in 4 groups of mice 18 days prior to
imaging. (a)-(b) Targeted CuNPs group: mice received αvβ3-CuNPs just before PA imaging. The enhanced
neovasculature is marked by arrows in B. (c)-(d):Nontargeted CuNPs group: mice received nontargeted
CuNPs right before PA imaging. (e)-(f):Competition group: mice received a competitive dose of αvβ3-oil
only NP (1:1) 10 minutes prior to imaging, followed by αvβ3-CuNPs right before imaging. (g)-(h) FumPD group: mice received αvβ3-CuNPs with Fum-PD 11 and 15 days after the Matrigel implantation, and
αvβ3-CuNPs w/o Fum-PD right before PA imaging. Comparing the PA images of the nontargeted,
competition, and Fum-PD groups at 0 min and 170 min, very little change in PA signals can be found. For
all PA images, laser wavelength = 767 nm.

Figure 4.7 presents the average change in the vessel-integrated PA amplitude between the three
treatment groups, showing that the ανβ3-CuNPs increased PA contrast, while the nontargetedCuNP did not (p<0.05). Moreover, the specificity of targeting the neovasculature was again
demonstrated by the low vessel-integrated PA amplitude measured in the competition group versus
the ανβ3-CuNP group (p<0.05), and even relative to the nontargeted control. Dynamic
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accumulation of PA contrast measured in the ανβ3-CuNP group increased progressively over the
230 minutes post injection interval (Figure 4.8).

Figure 4.7 Blood vessel PA signal at 170 min post-injection for four groups of mice. The blood vessel PA
signal (normalized to the baseline, i.e., blood vessel PA signals at 0 min) increase for the αvβ3-targeted
group was greater (*P<0.05) than that of the other three groups. Almost no blood vessel signal increase was
measured in the competition group, and a slight increase of blood vessel signal was observed in the nontargeted and Fum-PD groups.

Figure 4.8 Blood vessel PA signal vs. post-injection time for the αvβ3-CuNPs group. The blood vessel
signal increased progressively over the 230 min post injection interval.
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In a second aspect of the Matrigel™ angiogenesis experiment, fumagillin-prodrug (Fum-PD), 70,71,
was incorporated into the phospholipid surfactant at 2.28 mol%. The chemical synthesis,
characterization, and in vivo effectiveness of Fum-PD incorporated into perfluorocarbon
nanoparticles has been previously reported.

65,72

ανβ3-CuNP (2 µl/g) incorporating Fum-PD was

administered on days 11 and 15 post Matrigel™ implant, and the vessel-integrated PA amplitude
in these animals was determined on day 18. At baseline, the amount of neovasculature observed
by PA imaging was sparse, but no more so than that in the other groups. Moreover, following α νβ3CuNP injection there was little sprout enhancement at 170 minutes. As shown collectively in
Figure 4.6 and Figure 4.7, the vessel-integrated PA amplitude change was similar to that measured
in the nontargeted-CuNP group, and appeared related to modest particle accumulation in the
nascent tubules, with less signal related to sprout formation. Although drug delivery and imaging
were not performed simultaneously to minimize the differential animal handling between the
groups, these results illustrated the potential of CuNPs as vehicles for drug delivery and diagnosis.

4.4 Discussion
Photoacoustic imaging has demonstrated broad applications in the imaging and physiological
characterization of the vasculature, particularly the microvasculature

59,73

, and microvascular

expansion driven by brain tumor hypoxia 74. The vascular endothelium provides numerous “roadsigns” reflecting its developmental stage, as seen for the neovasculature, or its state of activation,
as seen with inflammation. In each instance, specific PA characterization depends on molecular
imaging through the recognition of unique endothelial biomarkers. 61,62,68,75-79 In the present study,
sparse activated ανβ3-integrin was selected as a biomarker of angiogenesis. While we have
previously reported dynamic imaging of the forming neovasculature with gold nanobeacons, the
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high and unpredictable cost of gold, and the unclear long-term safety of larger nonmetabolizable
nanoparticles, such as carbon fullerenes or nanotubes, led to the design and development of
CuNPs. While free copper can elicit systemic toxicity, CuNPs are comprised of high densities of
small organometallic complexes that can be eliminated through the bile or urine, minimizing the
risk potential for this agent.80 In the present study, CuNPs offered comparable PA contrast
enhancement, on an equal particle basis, to GNBs both in vitro and in vivo.
In vivo PA imaging was performed at 767 nm, which was optimal for the previously targeted GNB
agent, but the spectral assessments of CuNP relative to blood and as a function of particle
concentration suggest 740 or 750 nm may be preferred for targeting sparse epitopes like adhesion
molecules. Also, the time for maximum neovascular signal was found to be nearly 4 hours in the
Matrigel model, but similar particles administered in vivo for deeper-tissue angiogenesis imaging
with MRI were shown to provide minimal targeting benefit after 2 hours. 81,82 The difference likely
relates to vascular vasoconstriction with reduced blood flow to the skin in the subcutaneous
Matrigel implant model, which is aggravated by the cooling effects of acoustically coupling the
PA probe to the body during anesthesia, despite provision of supplemental heating to maintain
core body temperatures. Lastly, CuNPs were designed to be vascular constrained agents to reduce
nonspecific signal generated by interactions with extravascular cells expressing the α νβ3-integrin.
Close examination of the 170-minute PA images in Figure 4.6 showed negligible extravasation of
the particles. Although much attention has been attributed to the leakiness of angiogenesis, even
in the sprouting regions where the neovasculature is essentially open-ended, no evidence of
nanoparticle accumulation beyond the tips of the forming neovessel branches was noted.
Moreover, this was a consistent observation, regardless of whether the nanoparticles were integrintargeted or not.
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Fumagillin prodrug was incorporated into the phospholipid surfactant of CuNPs and demonstrated
to elicit anti-angiogenic effects in this Matrigel model. Microanatomically, the treatment virtually
eliminated the rich web of sprouts in the mice receiving α νβ3-CuNPs without Fum-PD. “Pruning”
of neovasculature was first suggested by Jain in a visionary manner, but in this study, the concept
was visually apparent. 83-85 Despite all of the extensive clinical research on the effects and benefits
of anti-angiogenesis therapy in cancer and selected other pathologies, virtually all of the work has
centered on vascular endothelial growth factor (VEGF) inhibition. While VEGF is a clear driver
of angiogenesis, it elicits pleotropic effects and is not solely responsible for neovascularization. 86
Moreover, VEGF is produced by a variety of cell types, making effective blockade of the growth
factor challenging. Typically, relatively high dosages of medicants are used clinically and these
treatments have well known side-effects. 87
As reported by others, fumagillin is an antiangiogenic agent which is specific for proliferating
endothelial cells, but its clinical analogue, TNP-470, possessed only antidotal effectiveness in the
clinic at the high doses required, which were accompanied by numerous toxicities, including
neurocognitive dysfunction. 88-90 Fumagillin can be effectively incorporated into the phospholipid
surfactant of nanoparticles for targeted delivery of anti-angiogenesis therapy through a mechanism
referred to as “contact facilitated drug delivery” (CFDD) at a small fraction of the dosages
previously used systemically. 48,91,92 Tethering of the lipid-encapsulated nanoparticle to the target
cell surface facilitates the interaction and hemifusion of the two lipid membranes, which affords
the passive transfer of the drug and phospholipids from the nanoparticle surface to the outer leaflet
of the target cell membrane. The drug is then translocated to the inner leaflet through an ATPdependent mechanism. 93,94 CFDD eliminates the need for particle internalization with subsequent
endosomal drug payload escape.
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However, pharmacokinetic studies showed that fumagillin dissolved into the lipid membrane was
substantially lost prematurely during circulation to the target neovasculature, despite its
effectiveness in vivo. Fum-PD was developed to address this early release by coupling the drug
through the Sn 2 acyl position (i.e., the stereospecific hydroxyl group of the second carbon of
glycerol). Subsequent transfer of the monolayer components into the target cell membrane allows
cytosolic phospholipases to enzymatically cleave the Sn 2 ester and release the drug, allowing it
to diffuse into the cytosol for effect. Fum-PD as well as other similar prodrug compounds is
incorporated stably into the hydrophobic aspects of the particle membrane. Importantly, Sn 2
lipase-labile prodrugs within the particle lipid membrane are stable in blood and plasma, even in
the presence of excess exogenous lipase, and do not passively exchange to co-circulating RBC.

95

The results of the present research show the first example of a systemically targeted antiangiogenic
drug delivery with a photoacoustic contrast nanoparticle. Given the rapid developments in
hardware and software for PA imaging, one can envision numerous medical applications for lowcost CuNPs particles to target neovascular or alternative endothelial biosignatures for diagnostic
and theranostic purposes.
Unlike current VEGF inhibitors, fumagillin-prodrug specifically targeted to angiogenic vessels
suppresses angiogenesis, clinical disease, and inflammation in a preclinical model of rheumatoid
arthritis (RA). [50] Enhanced endothelial nitric oxide (NO) modulates local macrophage
inflammatory activity through NO activation of AMP-activated protein kinase (AMPK). In vivo,
NO-induced AMPK activation increased autophagy by inhibiting mammalian target of rapamycin
(mTOR) activity. Increased autophagy mediated the degradation of IkappaB kinase (IKK) and
suppressed NF-κB. The suppression of NF-κB was associated with diminished inflammatory
cytokine release. Importantly, the NO mediated inhibition of inflammation was reversed in vitro
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and in vivo by the co-administration of N(G)-nitro-L-arginine methyl ester (L-NAME), a nitric
oxide synthase inhibitor. These unique anti-angiogenic and anti-inflammatory properties of FumPD nanotherapy may be applicable to the treatment of other angiogenesis-dependent diseases.

4.5 Conclusions
Soft copper oleate nanoparticles were synthesized and conceptually shown to offer effective
photoacoustic contrast comparable to gold-based agents, but at a much lower cost and higher
material availability. CuNPs possessed strong PA contrast relative to blood from 730 nm to 830
nm, which was similar to the PA signal response of gold nanobeacons relative to blood overall. In
the Matrigel angiogenesis model, ανβ3-CuNPs markedly enhanced neovessel tubules and identified
a myriad of incomplete emergent neovascular sprouts, which were not well detected or specifically
differentiated as angiogenesis with inherent PA imaging. ανβ3-CuNPs effectively delivered
fumagillin-prodrug, a potent anti-angiogenic therapy, in vivo, providing the first example of a
systemically targeted drug delivery therapy with a photoacoustic contrast agent.

54

Chapter 5 Photoacoustic Voltage Imaging
with a Synthetic Dye
In this chapter, we extend photoacoustic functional imaging, formerly based on hemoglobin to
include a voltage sensitive dye. We validate dye functions in HEK293 cells, and mouse brains in
a epilepsy model and a cortical electrical stimulation model. The work of this chapter is based on
the joint work of Bin Rao and it is under review.

5.1 Background
A human brain generates thoughts, perceptions, memories, actions, and emotions based on
environments and experiences, while defining each individual person. Despite the similarities of
human brains, the detailed connections and interactions of brain neuron circuits are uniquely
shaped by a person’s life. Understanding the brain will not only significantly advance human
knowledge, but also catalyze new treatment modalities for devastating brain diseases such as
Parkinson’s disease96-98 and Alzheimer’s disease99,100.
To decipher human brains, we need to measure neuronal activity with higher precision, and over
much larger spatial and temporal scales than currently achievable. However, current voltage
recording tools, including electrodes and

optical microscopes, are underdeveloped.

Microelectrodes and macro-electrodes are workhorses in recording neural voltage response signals
and stimulating neural tissue101,102 in clinics and labs. But they are limited by the small number of
practicable simultaneous recording points and they cannot interrogate tiny neuronal circuit
components such as dendrites and axon terminals. More recently, non-invasive optical methods
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for recording activity in large numbers of neurons have been significantly improved 103,104. Optical,
chemical, and genetic sensors have enabled scientists to study microcircuits and understand subcellular neurochemical dynamics in dendrites and axons103-108. Despite recent innovations in
optical sensors18-19 and non-invasive optical imaging instruments, much brain research with noninvasive optical methods is confined to the neuronal circuits of the top layer of the brain 109. In vivo
imaging of deep brain neuronal tissue and neuronal activity remains an unmet challenge.
Photoacoustic tomography6,59,110-112 (PAT) is a hybrid optical imaging method that detects
acoustic responses excited by laser pulses of both ballistic and diffused photons and achieves highresolution optical-contrast tomography at imaging depths beyond the optical diffusion limit.
Specifically, optical absorbers at all imaging depths absorb pulsed laser energy and radiate
photoacoustic waves that are detected by acoustic sensors for rendering three-dimensional images
of the optical absorbers. Although PAT is a versatile optical imaging modality, its potential in
imaging voltage responses of neuronal activities has never been explored.
In this communication, for the first time, we demonstrate photoacoustic voltage response imaging
contrast by using a non-radiative voltage sensor (dipicrylamine, or DPA for short). By using
spectroscopic photoacoustic tomography at isosbestic wavelengths, we can successfully separate
the voltage response signals from the hemodynamic signals on live brain surfaces. We demonstrate
the photoacoustic detection of HEK293 cell membrane voltages through 4.5 mm thick ex vivo rat
brain tissue. Although the current voltage dye (DPA) does not immediately allow in vivo deep
brain voltage response imaging, we believe our method opens up a feasible technical path for deep
brain studies in the future.
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5.2 Methods
5.2.1 Methods for Phantom Study and Live Cell Imaging
Method for recording DPA responses to different cell membrane resting potentials Cell
membrane resting potentials were adjusted by changing the extracellular potassium ion
concentration. The membrane potential change (∆ ) is roughly estimated by
∆ =

where
and

is the universal gas constant,

ln

,

is the absolute temperature,

(5.1)

is the Faraday constant, and

are the adjusted and initial potassium concentrations. Equation (5.1) is derived from

the Nernst equation, with the assumptions that the internal ion concentrations remain constant
during the short exposure to increased extracellular potassium ion concentration and that the
impact of the Na+ channel is disregarded113,114.
The stock DPA dye solution is 2 mM DPA (Biotium) in DMSO. The DPA stock solution was
diluted to 5 μM for in vitro cell culture experiments. The initial extracellular medium was made
by adding 20 mM HEPES and 5 μM DPA to Hanks’ Balanced Salt Solution (1.3 mM CaCl 2, 5.4
mM KCl, 0.4 mM KH2PO4, 0.5 mM MgCl2, 0.4 mM MgSO4, 136.9 mM NaCl, 0.3 mM Na2HPO4,
4.2 mM NaHCO3, and 5.5 mM glucose), and adjusting its pH to 7.4. Four adjusted extracellular
media with potassium concentrations of 12.7 mM, 61.4 mM, 134.8 mM, and 296.0 mM were
prepared by adding more KCl to the initial extracellular medium in order to adjust the cell
membrane resting potentials by 20 mV, 60 mV, 80 mV, and 100 mV, according to Equation (5.1).

57

Human embryonic kidney 293 (HEK293) cells were cultured in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum and incubated at 37 °C with 5% CO 2. For
photoacoustic microscopy, HEK293 cells were plated into a 35 mm glass-bottom petri dish
(P35GCOL-0-14-C, MatTek) one day before the experiment. Prior to PAM imaging, 5 μM DPA
was added to HEK293 cell culture medium (DMEM) and HEK293 cells were stained for 40
minutes. Baseline PAM images corresponding to a 0 mV cell membrane resting potential change
were acquired with the initial extracellular medium. Then the medium was sequentially replaced
by extracellular media with potassium concentrations of 12.7 mM, 61.4 mM, 134.8 mM, and 296
mM, and immediately imaged by a transmission-mode photoacoustic microscope (Figure 5.1) after
each replacement. Before each replacement, we reset the DPA concentrations stained on the
HEK293 cells by replacing the old medium with Hanks’ Balanced Salt Solution (no DPA). A
waiting time of 5–15 minutes, and occasionally multiple resets, were sometimes required for the
photoacoustic signals from the HEK293 cells to subside to the baseline. The means and standard
errors of photoacoustic signal amplitudes from the HEK293 cells corresponding to five different
resting potentials were calculated and analyzed.

Figure 5.1 Experimental setup for in vitro photoacoustic cell membrane potential imaging
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Experimental setup for in vitro photoacoustic cell membrane potential imaging

A

transmission-mode optical-resolution photoacoustic microscope (Figure 5.1) was used for in vitro
voltage imaging of the HEK293 cell membranes. In Figure 5.1, an integrated diode-pumped Qswitched laser and optical parametric oscillator (OPO) system (NT242-SH, Ekspla) generate laser
pulses (5 ns pulse width, 1 kHz pulse repetition rate) at 488 nm. The laser pulse is expanded and
then focused by a 4x objective (Zeiss, 0.1 NA). The focused laser light induced an abrupt
temperature rise in an illuminated absorber and excited photoacoustic waves, which are
acoustically coupled by deionized water and detected by an ultrasonic transducer. The
photoacoustic signal is amplified, digitized, and recorded. By raster scanning the sample with an
X-Y scanning stage, a three-dimensional image of the sample is formed. A depth-encoded
maximum-amplitude projection (MAP) image of the 3D data set shows the image in 2D format.

5.2.2 Methods for In Vivo Photoacoustic Voltage Imaging
Principle of separating voltage response signals from hemodynamic signals in live brain
The amplitudes of brain photoacoustic signals from hemoglobin and DPA dye excited by
a nanosecond laser pulse are written as
p
p

= αξΓm
= αξΓm

μ

(5.2)
μ

(5.3)

where the subscripts Hb and DPA denote hemoglobin and DPA respectively, p denotes the
amplitude of the photoacoustic signal, α is a spatially dependent factor, ξ is a coefficient
representing distortion and attenuation of the photoacoustic signal, Γ denotes the Grϋneisen
parameter of the medium, m denotes the molar concentration, μ denotes the molar optical
absorption coefficient of hemoglobin, and

denotes the local optical fluence in J/m2. The molar
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optical absorption coefficients of hemoglobin and DPA dye are known. The molar concentrations
of hemoglobin and DPA are unknown. In order to separate DPA signals from hemodynamic
signals, two measurements are required to solve the equations of the two absorbers.
For our two measurements, we selected two isosbestic wavelengths of hemoglobin (500 nm and
570 nm), where oxygenated and deoxygenated hemoglobin molecules have the same molar
absorption coefficient values. Hence, the photoacoustic signals are dependent on the total
concentration of hemoglobin only and are independent of the oxygen saturation of hemoglobin
(i.e., the ratio of the concentration of oxygenated hemoglobin to the concentration of total
hemoglobin). The laser fluence

was considered as constant after the calibration procedure

described later in the in vivo experiments. We define M

= αξΓm

and M

= αξΓm

as the relative measurements of the concentrations. For the first measurement at 500 nm and the
second measurement at 570 nm, we have the following:
μ

M

+μ

M

=p

(5.4)

μ

M

+μ

M

=p

(5.5)

Here, the subscripts 500 and 570 indicate the corresponding wavelengths in nm. The relative DPA
and hemoglobin concentrations are computed as follows:
M

M

= (p

= (p

−

−

p

)/ μ

p

)/ μ
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−

−

μ

(5.6)

μ

(5.7)

The method for separating DPA and hemoglobin signals with the above equations was successfully
tested by measuring phantoms with preset concentrations, as detailed in the supplementary
information.
Method of recording in vivo mouse brain response to electrical stimulation

We

constructed a PAM for in vivo mouse brain imaging. As shown in figure 5, the excitation light
sources are (1) an OPO laser system (NT242-SH, Ekspla) and (2) a dye laser (Credo, Sirah) tuned
to 570 nm and pumped by a 532 nm Nd:YLF laser (INNOSLAB, Edgewave). The 570 nm laser
pulse is delayed by 1 µs relative to the 500 nm laser pulse. A dichroic mirror combines the 500 nm
and 570 nm laser beams. To calibrate the fluctuations of laser pulse energy, a beam splitter splits
10% of the laser energies to a transmission-mode optical-resolution photoacoustic microscope that
uses a black tape as sample. The remaining 90% of the laser energy is delivered to a miniature
photoacoustic imaging probe comprising an achromatic lens (AC064-013-A, Thorlabs) and a
customized ring-shaped focused ultrasonic transducer. The mechanical design of the miniature
photoacoustic imaging probe allows adjusting the ring transducer for confocal optical and acoustic
foci. During imaging, the ring transducer is immersed in the water tank, with a plastic membrane
as its bottom. Electrical stimulation electrodes (MX216FW, FHC) are inserted around the edge of
the cranial window. Stimulation pulses are sent by an electrical stimulator (Micro-stimu III, World
Precision Instruments).
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Figure 5.2 Experimental setup for in vivo photoacoustic mouse brain imaging

The animal preparation is detailed in the supplementary material. All experimental procedures
were carried out in conformity with laboratory animal protocols approved by the Animal Studies
Committee at Washington University in St. Louis. For in vivo mouse brain experiments, we diluted
the stock DPA dye solution of 2 mM DPA (Biotium) in DMSO to 20 μM. Before photoacoustic
imaging, 20 µM DPA was applied to the cranial window for 30 minutes of bath staining. For in
vivo imaging, acoustic gels were placed between the plastic membrane of the water tank and the
mouse brain. Initial 3D mouse brain imaging with the OPO laser tuned to 532 nm allowed us to
select an M-mode imaging point that appeared to have minimum vasculature. To acquire baseline
photoacoustic signals without stimulation, we performed M-mode recordings with dual
wavelengths at the selected point. After that, M-mode recordings were collected at the same point
during electrical stimulation, and then the photoacoustic responses from hemoglobin and DPA
were calculated from Equations (5.6) and (5.7).
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Method of recording in vivo mouse brain response to epilepsy induced by 4-Aminopyridine
We used the same PAM setup to image the mouse brain in vivo in response to epilepsy
induced by 4-aminopyridine (4-AP). Similar to the method used in the electrical stimulation model,
a cranial window was created in the mouse skull and 20 µM DPA was applied to the cranial
window for 30 minutes of bath staining. After raster-scan imaging the mouse brain through the
cranial window, we selected a point without noticeable interference from blood vessels. A baseline
M-mode recording with dual wavelengths was obtained at that point, then 50 µL of 4-AP was
injected through the cranial window into the brain cortex to induce focal seizure. After the
injection, a raster-scanned image was acquired again to locate the M-mode imaging point. We
waited until a visually observable seizure response occurred, and started M-mode recordings of
the same location with dual wavelengths. Last, the photoacoustic responses from the hemoglobin
and DPA were calculated from Equations (5.6) and (5.7).
Animal preparation Adult Swiss Webster (Hsd:ND4) mice were used for all in vivo imaging
experiments. During the surgery, the mouse was first secured using a tooth bar on a platform and
maintained under anesthesia with 1.5–2.0% vaporized isoflurane. The scalp of the mouse brain
was removed. Then cyanoacrylate glue was applied to the gap between the back of the mouse’s
head and an aluminum plate with a “U” shaped dent as shown in Figure 5.3. Because the plate was
secured to the platform, motions of the mouse head relative to the imaging setup were avoided. A
3 mm by 3 mm cranial window was then created on the mouse skull, and the isoflurane level was
decreased to ~0.5% after surgery. For an electrical stimulation experiment, stimulation electrodes
were inserted at the edge of the cranial window and fixed on the skull surface with cyanoacrylate
glue. For a 4-Aminopyridine (4-AP) drug stimulation experiment, direct injection of 4-AP in the
neocortex layer within the cranial window was used to induce epilepsy. 20 µM DPA dye was
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injected into the cranial window, and 20 minutes of staining time was waited before imaging. After
the imaging procedures, the animal was euthanized. All experimental procedures were carried out
in conformity with laboratory animal protocols approved by the Animal Studies Committee at
Washington University in St. Louis.

Figure 5.3 Schematic of animal preparation

5.2.3 Method of Imaging HEK293 Cell Clusters Through Thick Ex Vivo
Brain Tissue
We used a photoacoustic computed tomography (PACT) system to demonstrate that PACT can
potentially image deep brain voltage responses.

Figure 5.4 PACT setup for imaging in vitro HEK293 cell clusters through ex vivo thick brain tissue

The photoacoustic computed tomography (PACT) setup for imaging in vitro HEK293 cell clusters
through ex vivo thick brain tissue is shown in Figure 5.4. 488 nm nanosecond (ns) pulsed laser (10
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ns pulse width, 3 mJ laser pulse energy) is generated by an OPO laser. The collimated laser beam
passed through ex vivo thick brain tissue before reaching the HEK293 cell clusters in an agarose
tube. Upon laser excitation, photoacoustic waves generated by the HEK293 cells (stained with
DPA) are detected by a circular transducer array (5 MHz central frequency, 512 elements). A backprojection algorithm is used to reconstruct PACT images
To mimic imaging through different thicknesses of brain tissue, a whole brain was harvested from
a sacrificed rat (Sprague Dawley®, Charles River). The whole rat brain was embedded in agarose
before being cut into slices either 1 mm or 0.5 mm thick by a vibrating blade microtome (Leica
VT 1200 S). Only central slices with relatively large areas were used to construct ex vivo brain
tissue layers between 2 mm to 5 mm thick. HEK293 cells that were initially grown in a T-75 flask
were washed off with trypsin, immersed in Dulbecco’s Modified Eagle’s Medium (with no phenol
red), stained with 5 μM DPA, incubated for 20 minutes in a CO 2 incubator (37° C, 5% CO2), and
distributed among six 15 ml agarose tubes. The HEK293 cell clusters in the first agarose tube were
imaged through different thickness of brain tissue (0.0 mm, 2.0 mm, 3.0 mm, 4.5 mm, and 5. mm)
in order to determine the maximum thickness of brain tissue through which HEK293 cell clusters
remained visible. The extracellular potassium concentrations in five other agarose tubes were
adjusted to achieve 0 mV, 40 mV, 60 mV, 80 mV, and 100 mV of cell membrane voltage changes.
HEK293 cell clusters were then imaged through brain tissue of the determined maximum
thickness. The calculation of CNR for figure 4a includes the following steps:
(1) We define the background:
backgr = mean (PA amplitudes outside the cell area).
(2) We define signals from the cell area:
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signal = mean((PA amplitude>= backgr) within the cell area).
(3) We define the baseline signals from the cell area:
base = mean((PA amplitude < backgr) within the cell area).
(4) We define noise as the standard deviation within the background area:
noise = stdev(PA amplitudes outside the cell area).
(5) Last, we calculate the CNR:
CNR = (signal-base)/noise.

5.3 Results
5.3.1 Photoacoustic Imaging of Live Cell Membrane Potentials and Phantom
Study
Hydrophobic anions, such as DPA and sodium tetraphenylborate (TphB), have extremely strong
adsorption to plasma membranes, and their adsorption and transport mechanism in the lipid bilayer
membrane have been well studied115,116. So far, DPA has been found to induce voltage-dependent
membrane capacitance in the squid giant axon29 and to report neuron cell membrane potentials117123

in fluorescence imaging. We wondered if it could be used as a voltage sensor for photoacoustic

tomography. Thus, we conducted an in vitro HEK293 cell imaging experiment with a transmission
mode optical-resolution photoacoustic microscope (Figure 5.1), as detailed in the Methods. With
0.3 NA objective, the PA images of HEK293 cells stained with DPA shows the dyes enhanced the
PA signals of cell membrane. With the increased cell membrane potential, the PA signals of the
cells also increased (Figure 5.5).
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Figure 5.5 PAM of HEK293 cells stained with DPA at different membrane potentials

To quantify the relationship between PA signal change and cell membrane potentials, we measured
the PA signals from a group of HEK293 cells at a series of different cell membrane
potentials(Figure 5.6). The dashed ellipse in Figure 5.6(a) identifies a HEK293 cell cluster. The
larger the HEK293 cell membrane resting potential change, the larger the photoacoustic signal
change. Figure 5.6(b) quantifies the fractional photoacoustic signal changes due to cell membrane
voltage changes estimated from the Nernst equation. First, we calculate the averaged PA signal for
cells within the dashed ellipse for each image. Second, we compute the fractional PA signal change
by normalizing the PA signal change by the initial PA signal under the initial membrane potential.
A fractional photoacoustic signal increase greater than 40% was recorded for a 100 mV membrane
resting potential change. Because the Nernst equation overestimates voltage change 114, an even
larger fractional photoacoustic signal change was expected for a given membrane resting potential
change. It is worth noting that we might have a slightly different PA voltage response curve in
Figure 5.6(b) if the more accurate Goldman equation is used. Pursuing quantitative PA voltage
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imaging, which requires further calibration experiments with a voltage clamp instrument, is
beyond our current scope.

Figure 5.6 PAM of live HEK293 cells at different membrane potentials (a) Photoacoustic maximumamplitude projection images of HEK293 cells demonstrate photoacoustic signal changes due to cell
membrane voltage changes. (b) Fractional photoacoustic signal change versus cell membrane resting
voltage changes.

The PA signal can be written as p = αξΓmμ , where p denotes the PA signal, α is a spatially
dependent factor, ξ is a coefficient representing the distortion and attenuation of the photoacoustic
signal, Γ denotes the Grϋneisen parameter of the medium, m denotes the molar concentration of
DPA, μ denotes the molar optical absorption coefficient of DPA, and
fluence in J/m2. Because α, ξ, Γ, and

denotes the local optical

are parameters not affected by plasma membrane voltage,

the PA voltage response contrast must originate from either the molar concentration (m) or the
molar optical absorption coefficient ( μ). In the case of the voltage-dependent molar optical
absorption coefficient ( μ) , a voltage-dependent optical absorption spectrum is expected. To
investigate whether the voltage-sensitive mechanism is due to the molar optical absorption
coefficient ( μ), we performed photoacoustic spectroscopy of the DPA-stained HEK293 cell
membrane under two different resting potentials.
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To investigate whether the voltage-sensitive mechanism is due to µ, we first varied the excitation
wavelength of the OPO laser from 400 nm to 570 nm to acquire the PA spectrum of DPA molecules
stained on the HEK293 cell membrane under a 0 mv membrane potential. Next, we acquired the
PA spectrum under a 56 mv membrane potential after the external K+ concentration was adjusted.
Figure 5.7 shows two normalized PA spectra of DPA molecules in the HEK293 cell membrane
between 400~570 nm for 0 mv (blue solid line) and 56 mv (red dashed line) cell membrane
potentials. The error bars identify the standard deviation of the measurements. Statistically, we
conclude that the normalized PA absorption spectrum remains unchanged when the two different
membrane potentials are applied.

Figure 5.7 PA spectrum of HEK293 cells stained with DPA. (a) PA images of HEK293 cells at a wavelength
of 488nm for 0 mv and 56 mv cell membrane potentials. (b) Two normalized PA spectra between 400 –
570 nm.

Therefore, we concluded that the normalized photoacoustic absorption spectrum did not change
with membrane voltage, which leaves, as the other hypothesis, that the molar concentration (m)
of DPA in lipid membrane is voltage-dependent. This voltage sensitive mechanism is very close
to repartitioning18, a fluorescent voltage sensitive scheme that solely involves dye molecules
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moving in and out of the lipid membrane with voltage changes. The only difference is that the dye
molecules involved here are non-fluorescent.
To further prove the DPA voltage contrast mechanism, we performed another experiment based
on spectrophotometry instead of photoacoustics. We stained HEK293 cells with 5 µM DPA
solutions with different K+ concentrations. The total number of DPA molecules, including DPA
adsorbed onto plasma membrane and DPA in solution, remained constant. By quantitatively
measuring the DPA molecules left in the solution with spectrophotometry, we calculated the DPA
molecules adsorbed to the membrane under different membrane voltages. The number of DPA
molecules adsorbed on HEK293 cell membranes equals the total number of DPA molecules minus
the number of DPA molecules in the solvent. The number of DPA molecules in the solvent was
measured by a spectrophotometer after centrifuging and sampling operations. The measurement
results, shown in Figure 5.8, agree with the photoacoustic measurement results. More DPA
molecules are adsorbed to cell membranes as the cell membrane voltage change increases.

Figure 5.8 Normalized DPA absorption change versus relative membrane voltage change

Both

spectrophotometric results

and

photoacoustic

results

agreed

well.

Thus,

the

spectrophotometry confirmed repartitioning, i.e., that more DPA molecules are adsorbed to the
cell membrane when the resting potential change is higher, which leads to stronger photoacoustic
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signals. Finally, we conclude that repartitioning of DPA molecules is the voltage sensitive
mechanism behind the PA voltage response contrast. This type of voltage sensitive mechanism is
considered not fast enough for imaging dynamic action potentials of neurons. The frequency
response of the DPA dye could be modeled as the low-pass filtered frequency response of an
ordinary voltage dye.
Calculating blood and DPA concentration in mixed solutions in tubes To prove the accuracy
of differentiating blood and DPA signals spectrally using our theories, we perform the phantom
study for mixtures of blood and DPA. A 20 mM DPA solution was purchased from Biotium Inc.
Lysed bovine blood was purchased from QuadFive.com. DPA and blood mixture phantoms were
made by mixing varied concentrations of DPA in a diluted lysed blood solution and injecting it
into a laboratory tube (CAT. No. 508-001, Dow Corning) with 0.3 mm inner diameter and 0.64
mm outer diameter. The preset DPA molar concentrations and blood volume concentrations for
two groups of phantoms are shown in table 1.
Table 5.1 Preset DPA and blood volume concentrations for two groups of phantoms
Group 1

Tube 1

Tube 2

Tube 3

Tube 4

Tube 5

DPA

0 mM

0.1 mM

0.2 mM

0.5 mM

1.0 mM

Blood

10%

10%

10%

10%

10%

Group 2

Tube 6

Tube 7

Tube 8

Tube 9

Tube 10

DPA

0.2 mM

0.2 mM

0.2 mM

0.2 mM

0.2 mM

Blood

10%

90%

20%

40%

80%

71

We performed calibration with two phantoms in each group and plotted both preset points and
measured points in 2D concentration-space. Figure 5.9 shows the measured DPA molar
concentration of tubes of group 1 versus the preset values. Figure 5.9b shows the measured volume
concentrations of blood in tubes of group 2 versus the preset values. The phantom experimental
results prove that our method of separating DPA and blood signal is valid.

Figure 5.9 Measured DPA and blood concentrations versus preset values

Estimating DPA concentration in cell membranes in vivo

For in vivo experiments, 20

µM DPA was used to stain mouse brain through the cranial window. However, the effective DPA
concentration on the brain surface was significantly higher than 20 µM because of the strong
adsorption of DPA by the lipid membrane. To estimate the effective DPA concentration in lipid
membrane, the ratio of the PA signal from 1 mM DPA dye and the PA signal from 20 µM DPA
stained lipid membrane of HEK293 cells was measured as 8.3. Thus, the effective DPA
concentration of the 20 µM DPA stained lipid membrane is 1 / 8.3 = 0.12 mM. Next, we performed
phantom experiments to test our method for separating DPA and hemoglobin signals.
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5.3.2 In Vivo Mouse Brain Surface Voltage Response to Electrical
Stimulation
Although DPA voltage dye is slow, we still could use it to record voltage responses in mouse
brains in vivo. One obstacle for PA voltage response imaging is the interference of hemoglobin in
blood. Deán-Ben XL et al. reported in vivo PAT imaging of GCaMP5G (a genetic calcium
indicator) zebrafish37. However, the contributions of hemoglobin and GCaMP5G in the PA signal
were mixed because of the well-known neuronal-vascular coupling effect. Here, we considered a
simplified case where the imaging target is the DPA stained dura layer immediately beneath the
mouse skull instead of neuron circuits inside the live brain. The laser fluence in the imaging voxel,
which includes both the dura and cortex tissue, is a constant after normalization against the
photodiode recording of laser pulse energy. For this simplified case, a spectroscopic method
provides exact solutions for both the hemodynamic signal, and voltage response signal, as detailed
in the Methods section. The analysis of calculation error presented in the SI, section VII, shows
that the calculation errors are less than 1.5 times the noise. This spectroscopic voltage response
imaging method is very similar to the spectroscopic oxygen saturation imaging method 38-39 that
was first verified with in vitro phantoms and then applied to in vivo applications. The technical
verification experimental results for the spectroscopic voltage response imaging method are
provided in the SI, section V. The voltage response signal is a low-pass filtered local field potential
signal, which has a high similarity within a relatively large area. Thus, we expect that motion
artifacts caused by respiration have minor effect on the measured voltage response signal.
As we know, electrical stimulation can change the neuronal membrane voltage and trigger a
neuronal response to extracellular electrical currents near the neuron 124-126. This stimulation
approach has been used to identify the motor cortex, map neural connections between brain
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regions, modulate attention, increase the speed of learning, identify neural subtypes, record
movement sequences, study somatosensory perception, and introduce signals directly into the
brain in brain-machine interface models. It was shown that micro-electrical stimulation sparsely
activates neurons around the electrode up to millimeters away from the point of stimulation 124.
Although we have a limited understanding of the effects of electrical stimulation on individual
neurons, it serves well for our purpose of voltage response signal imaging. DPA dye was applied
outside the intact dura matter. The depth-resolved photoacoustic microscopy image indicated that
photoacoustic signals come from the surface of the brain, including micro-vessels within the Mmode imaging voxel volume, where the laser fluence is a constant after normalization against the
photodiode recording of the laser pulse energy.
We also investigated the PA signal ratio between blood vessels and DPA stained tissues to make
sure that PA signals are not overwhelmed by the hemoglobin signals at 500 nm. Figure 5.10
compares the brain images at 500 nm before and after 20 µM DPA dye staining. The PA signal
change due to DPA dye staining is obvious because of the strong lipid membrane adsorption effect.
The mean PA signal before staining, from region d1, is dominantly from capillary blood vessels.
For region d1, the mean PA signal after DPA staining is dominantly from capillary blood vessels
and adsorbed DPA dyes. Thus, the dye signal at 500 nm is 730-603 = 127 (a.u.). We can estimate
the ratio of the hemoglobin signal to the DPA signal within region d1 as Equation (5.8).
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Figure 5.10 Effects of DPA staining on mouse cranial window

= 603/127 = 4.7

(5.8)

We can estimate the ratio at 570 nm from the known absorption curves of Hb and DPA:
=

(5.9)

=

= 2.143 ∗ 4.7 ∗ 19.8 = 200 (5.10)

At 570 nm, the hemoglobin signal is dominant. However, at 500 nm, the DPA dye contribution is
significant. With the spectroscopic method, the contributions from Hb and DPA can be separated.
At other labeled areas of Table 5.2, the ratio of

at 500 nm varies from 3.3 to 6.6.

Table 5.2 PA signals of blood vessels before and after staining with DPA
Mean PA signals (a.u.)

d1

d2

v1

v2

v3

Before

603

557

2469

2171

2652

After

730

677

3089

2826

3053

Difference

127

120

620

655

401

Ratio (Before/Diff.)

4.7

4.6

4.0

3.3

6.6
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The fact that PA signals from DPA stained tissue are not overwhelmed by the hemoglobin signals
at 500 nm allows the separation of the voltage response signal from the hemoglobin signal.

Figure 5.11 In vivo PA response of mouse brain before and during electrical stimulation at a minimally
vascularized point. (a) The exact M-mode imaging location is identified by the yellow cross in the depthcoded maximum amplitude projection image of the DPA-stained mouse cranial window. (b) A 63 second
stimulation sequence comprises 189 electrical stimulation pulses with a pulse width of 300 μs and a pulse
period of 333 ms. (c) Baseline (before electrical stimulation) and response (during stimulation) of voltage
and hemodynamic signals in the frequency domain. Both the voltage response signal (red) and
hemodynamic response signal (black) have observable frequency components at 3.1 Hz and 6.2 Hz. The
SNRs of the voltage and hemodynamic response peaks are respectively labeled with red and black text.

Then, we recorded in vivo mouse brain responses before and during electrical stimulation at a point
with minimum vasculature. In Figure 5.11(a), the exact M-mode imaging location is identified by
the yellow cross in the depth-coded maximum amplitude projection image of the DPA-stained
mouse cranial window. Figure 5.11(b) shows a 63-second electrical stimulation sequence that
comprises 189 electrical stimulation pulses with a pulse width of 300 μs and a pulse period of 333
milliseconds. There are no observable features in either the baseline (before electrical stimulation)
or response (during stimulation). We analyzed the baseline and response of the voltage and
hemodynamic signals in the frequency domain. Compared to the noise-like baseline signals, both
the voltage response signal (red) and hemodynamic response signal (black) have observable
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frequency components at 3.1 Hz and 6.2 Hz, as shown in Figure 5.11(c). The signal-to-noise ratios
(SNR) of the voltage and hemodynamic response peaks are labeled with red and black text,
respectively, next to the peaks. Because the voltage response signal (red trace) is stronger than
hemodynamic signal for both frequency components, the voltage response is dominant at this
minimally vascularized M-mode imaging point.
On the other hand, we can also estimate the PA signal response under electrical stimulation. We
assume the single pulse electrical stimulation function is written as:
, | |≤

( )=

(5.11)

0, | | > .

The Fourier-transformation of ( ) is the frequency-domain signal:
(

( )=

)

(5.12)

The electrical stimulation pulse train is written as the convolution of ( ) with a comb function:
ℎ( ) = ( ) ∗

( )

( )=∑
Here T is 300 µs and T’ is 333 ms, so

(5.13)

( −

)
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is 3 Hz. The Fourier-transformation of the pulse train h(t)

is
( )= ( )

( )=

(

∑
)
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−

∑

(5.15)

−

(5.16)

Thus, the pulse train stimulation has frequency components only at

, which is an integer

multiple of 3 Hz. If we model the voltage response of DPA dye on the dura layer as a linear low
pass filter for all frequency components less than 8 Hz, we end up with two frequency components
at 3 Hz and 6 Hz. Our analysis based on the model agrees with the observed PA voltage response
peaks at 3.1 Hz and 6.2 Hz. The experimental results have clearly shown that DPA is a slow dye,
which is not suitable for dynamic action potential imaging experiments.

5.3.3 In Vivo Mouse Brain Voltage Response Signal Imaging Before and
During 4-aminopyridine-induced Epilepsy
The drug 4-aminopyridine (4-AP) was used to induce epileptic seizure in various models of
epileptic seizure127-131. Epileptiform activity has been extensively studied using different optical
imaging methods132-141. Among these, photoacoustic tomography has the potential to record deep
brain voltage response signals and hemodynamic signals in parallel and to become a new tool for
understanding the induction, maintenance, and propagation of seizure discharges. Here, in an
animal model, we demonstrated the recording of both neuronal and hemodynamic responses to
epileptic seizure induced by 4-AP.
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Figure 5.12 In vivo mouse brain response before and during epilepsy. (a) The white cross identifies the Mmode recording point on the depth-encoded maximum amplitude projection image of the mouse brain
through the cranial window. The color represents depth. (b) Fractional voltage and fractional hemodynamic
signal changes in the time domain for the baseline (before 4-AP stimulation) and response (during 4-AP
induced epilepsy). The SNRs of the voltage and hemodynamic response peaks are labeled with red and
black text. The fractional voltage response signal change shows stronger responses (spike amplitudes) than
the fractional hemodynamic signal change.

Figure 5.12 shows a maximum amplitude projection image of a mouse brain through a skull
window after staining with DPA. The white cross identifies the location of M-mode imaging.
Figure 5.12(b) shows the calculated fractional photoacoustic voltage response signal change (red
trace) and the fractional hemodynamic signal change (black trace) before and after 4-AP induced
epilepsy. Before the induction of epilepsy, both the fractional voltage response signal change and
the fractional hemodynamic signal change show no observable events. However, the induced
epilepsy after the injection of 4-AP within the skull window generated significant spikes at the
same M-mode imaging location. We recorded a fractional photoacoustic voltage response signal
change of more than 300% and a fractional photoacoustic hemodynamic signal change of more
than 200%. We hypothesize that the significant voltage response signal change could be due to
synchronized neuronal firing during 4-AP induced epilepsy and that the significant hemodynamic
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signal change could be related to the recruitment of capillaries during epilepsy and the neuronalvascular coupling. We note that the voltage-sensitive mechanism of DPA dye reflects its voltagedependent adsorption to the lipid membrane. This mechanism is considered too slow to catch the
single action potentials fired by the epileptic neurons. The calculated fractional voltage response
signal change that has been low-pass filtered by the DPA dye could show only the entire epileptic
spike envelopes. Both the fractional voltage response signal change (red) and the fractional
hemodynamic response signal change (black) show spikes that are not necessarily always
synchronous. Over all, at the recording point, the fractional voltage response signal change shows
stronger responses than the fractional hemodynamic signal change.

5.3.4 Imaging HEK293 Cell Clusters Through Thick Ex Vivo Brain Tissue
In the above two in vivo imaging experiments, we demonstrated PA imaging of voltage responses
as a function of the brain surface voltage. In addition to the easy dye delivery and robustness
against respiration-caused motion artifacts, both animal models allow exact solutions of the
voltage response signal and the hemoglobin signal. In vivo deep brain voltage response imaging
remains very challenging without a long-wavelength voltage sensor whose optical absorption
spectrum can be separated from that of hemoglobin. However, the DPA voltage dye still allows us
to demonstrate in vitro PA voltage response imaging at depths beyond the optical diffusion limit.
A photoacoustic computed tomography system (see Methods) was used for this demonstration
experiment.
As described in the methods section, we first imaged HEK293 cell clusters through different
thicknesses of rat brain tissue. Figure 5.13(a) shows PACT images of HEK293 cell clusters
acquired through 4.5 mm and 5.0 mm thick rat brain tissues. The contrast-to-noise ratios (CNR)
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of the cell cluster images acquired through 0.0 mm, 2.0 mm, 3.0 mm, 4.5 mm, and 5.0 mm
thicknesses decrease with increasing thickness of brain tissue, as shown by Figure 5.13(b). The
calculation of CNR is detailed in the Methods section. We define the cell cluster visibility threshold
as CNR of at least 2. Consequently, the HEK293 cell clusters remain visible through 4.5 mm thick
rat brain tissue and become invisible through 5 mm thick rat brain tissue.

Figure 5.13 Imaging cell clusters through different thicknesses of ex vivo brain tissue with different resting
potentials. (a) HEK293 cell cluster PACT images through 4.5 mm and 5.0 mm thick brain tissue. (b) The
contrast-to-noise ratios of the HEK293 cell cluster images acquired through 0.0 mm, 2.0 mm, 3.0 mm, 4.5
mm, and 5.0 mm thick brain tissue decrease as the brain tissue thickness increases. (c) Photoacoustic images
of HEK293 cell clusters acquired through 4.5 mm thick brain tissue in response to cell membrane voltage
changes. (d) Fractional photoacoustic signal change versus cell membrane voltage change.

Second, we imaged HEK293 cell clusters in response to different cell membrane voltage changes
through 4.5 mm thick rat brain tissue. In Figure 5.13(c), stronger photoacoustic signals were
observed due to larger cell membrane voltage changes. The fractional photoacoustic amplitude
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change versus voltage change is plotted in Figure 5.13(d). There is more than a 60% fractional PA
amplitude change with 100 mV of cell membrane voltage change, which might have been caused
by the longer staining time when cell clusters were bathed in DPA solutions during the imaging
procedures.
Our results are still limited by the sensitivity and density of the ultrasonic transducer array device.
High-sensitivity, high-frequency optical sensors with excitation wavelengths outside of the
hemoglobin absorption spectrum will maximize the achievable imaging depth of PACT imaging.

5.4 Conclusions and Discussion
We report the first demonstration of photoacoustic voltage response imaging in both in vitro
HEK293 cell cultures and in vivo mouse brain surfaces. Using spectroscopic photoacoustic
tomography at isosbestic wavelengths, we separated voltage response signals and hemodynamic
signals on live brain surfaces. By imaging HEK293 cell clusters through 4.5 mm thick ex vivo rat
brain tissue, we demonstrated photoacoustic tomography of HEK293 cell membrane voltage
responses beyond the optical diffusion limit. Although the current voltage dye does not allow in
vivo deep brain voltage response imaging immediately, we believe our method opens up a feasible
technical path for deep brain studies in the future.
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Chapter 6 Photoacoustic Calcium Imaging
with a Genetically-encoded Indicator
In addition to voltage indicators, calcium indicators are also popular indicators for neural imaging.
Though calcium signals cannot faithfully represent membrane voltage changes, they are closely
associated with neural activities. With a large absorption coefficient and a strong signal change,
calcium indicators are widely used for measurements in highly scattering media. However, their
use for photoacoustic imaging was not demonstrated before this work. In this chapter, we use PAM
and PACT systems for calcium imaging with a genetically encoded indicator, GCaMP, and achieve
calcium imaging in a fly brain and live mouse brain slices.

6.1 Background
Monitoring the neural activity of large populations of neurons with fine spatial and temporal
resolution is arguably one of the most important challenges in neuroscience 142-144. To achieve this
goal, several multi-unit electrophysiological recording techniques

145-147

and optical imaging

methodologies148-150 have been developed in recent decades. Electrophysiological recording
methods are still considered the gold standard because they directly monitor intracellular or
extracellular neural signals from individual neurons or small groups of neurons with high
sensitivity and temporal fidelity151. Complementing these techniques, noninvasive optical imaging
techniques that allow larger spatial coverage with finer spatial resolution have been used to study
computations performed by neural networks148,152,153. In particular, two-photon microscopy,
combined with fluorescent calcium and voltage indicators, has enabled optical mapping of neural
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circuits from hundreds to thousands of neurons, with high spatiotemporal resolution in optically
scattering brain tissue150,154-157. However, several limitations still exist. For example, the point-bypoint scanning of confocal microscopy and two-photon microscopy creates a tradeoff between
spatial coverage and temporal resolution. More importantly, light scattering in the neural tissue
fundamentally restricts the current optical neural imaging methods to the superficial tissue layer
(~1 mm)59,158 To address this issue, invasive techniques using deeply implanted fiber-optic probes
have been recently used to image non-superficial regions inside the mouse brains 159-162. Therefore,
there is a strong need for noninvasive optical imaging methods that can break the optical diffusion
limit and provide rapid depth-resolved monitoring of neural activity.
Alternative to conventional optical imaging methods, photoacoustic tomography (PAT) has been
demonstrated as a powerful brain imaging technique capable of providing high-resolution images
with optical absorption contrast at depths far beyond the optical diffusion limit 59,163,164. Briefly,
PAT is based on the photoacoustic (PA) effect, which starts with optical absorption by molecules
in tissue and ends with ultrasonic emission through thermoelastic expansion59. Similar to
ultrasound imaging, PAT has inherent depth-resolved imaging capability based on the acoustic
arrival time or acoustic focusing. Because PAT is sensitive to optical absorption contrast (both
endogenous and exogenous), it is well suited for functional, molecular, and metabolic brain
imaging165. In addition, PAT is highly scalable in its spatial resolution, penetration depth and
imaging speed. Previous endeavors in PA brain studies have focused on measuring hemodynamic
parameters, including the blood vessel diameter, blood flow, total hemoglobin concentration, and
the oxygenation saturation of hemoglobin166-178, which are usually slow and indirect indicators of
neural activities through neurovascular coupling179. In contrast, intracellular calcium signals
respond to neural activities faster than hemodynamic signals, and can be recorded optically with
84

the help of intracellular calcium indicators180. Among all the calcium indicators, GCaMP, with its
relatively fast conformational change upon calcium binding during action potentials, is by far the
most widely used genetically encoded calcium-sensitive protein 181. The conformational change of
GCaMP results in a substantial increase in its optical absorption, which is ideal for PAT imaging
of calcium signals with high sensitivity. Still, it is yet to be determined whether experimental
results support this hypothesis and how the PA signals compare to the fluorescence signals.
Here, for the first time, we clearly demonstrate that PAT can be used to monitor neural activities
in select neurons expressing GCaMP indicators in transgenic invertebrate (fly) and vertebrate
(mouse) models expressing GCaMP indicators in selected neurons. To accommodate different
spatial scales, we adapted two PAT embodiments—photoacoustic microscopy (PAM) and
photoacoustic computed tomography (PACT). With PAM, we demonstrate high-resolution depthresolved neural imaging without depth scanning, which is desired for monitoring neural activities
with high temporal resolution. With PACT, we demonstrate wide-field imaging of GCaMP
calcium signals at depths beyond the optical diffusion limit. The combination of PAT and GCaMP
or other potential calcium indicators provides a promising platform for functional brain imaging
at different spatial scales.

6.2 Methods
PAT of neuronal calcium signals with GCaMP

In PAT, as tissues are excited by laser pulses,

laser energy is absorbed by biomolecules, and converted through both the fluorescence channel by
radiative relaxation and the PA channel by non-radiative relaxation. An ultrasonic transducer or
transducer array is used to detect the PA waves as they propagate out of the tissue. The detected
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PA signals are used to reconstruct an image that maps the original optical energy deposition due
to non-radiative relaxation in the tissue.
Based on the image formation methods, PAT has two major implementations. The first combines
mechanical scanning of a focused single-element ultrasonic transducer with direct image
formation, and is commonly used in PAM. The second combines parallel detection by a multielement ultrasonic transducer array or a mechanical/electronic scanning equivalent with image
reconstruction, and is used in PACT. In both PAM and PACT, the PA amplitude is proportional
to the optical absorption coefficient of the absorber in the unit of m–1, its non-radiative quantum
yield (approximately equal to 1 – the fluorescence quantum yield if the photochemical channel is
negligible), and the local optical fluence (or exposure) in the unit of J/m 2.
Two GCaMP variants were used in this study, GCaMP5G for fly brain imaging, and GCaMP6f
for mouse brain slice imaging. In general, GCaMP consists of a circularly permuted EGFP, an
M13 fragment of myosin light chain kinase, and a calcium binding site of calmodulin. Action
potentials trigger a large and rapid influx of Ca2+

182

. In the presence of calcium, calmodulin

interacts with the M13 fragment, eliciting a conformational change in EGFP and resulting in an
increase in its optical absorption coefficient

183,184

. Because the PA signal of GCaMP is

proportional to its absorption coefficient, PAT has a 100% sensitivity to the absorption change of
GCaMP upon the binding of Ca2+.
PAM of the fly brain in vivo

A dual-modality PA and epi-fluorescence microscopy

system shown schematically in Figure 6.1(a) was used to image the fly brain. A tunable OPO laser
(a 1-kHz pulse repetition rate, 5-ns pulse width; NT242-SH, Ekspla, Ltd.) provided 488-nm–
wavelength excitation light, which was collimated and coupled into a miniature imaging probe
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containing an achromatic focusing lens with a 13-mm focal length and a customized ring-shaped
ultrasonic transducer (a 40-MHz central frequency, ~100% bandwidth, and 6.2-mm focal length).
The laser beam formed a 6-μm optical focal spot confocally aligned with the acoustic focus of the
ring transducer. The axial resolution of the PAM, determined by the ultrasonic transducer
bandwidth, was calculated to be ~21 μm

185

. A beam splitter reflected the fluorescent light for

fluorescence imaging. The fluorescent light passed through another focusing lens (a 50-mm focal
length) and a bandpass filter (a 525-nm central wavelength, 39-nm bandwidth; Thorlabs, Inc.)
before being collected by an EMCCD camera (iXon Ultra 888, Andor, Ltd.). PA signals were
sampled by a 200-MHz data acquisition (DAQ) system (National Instruments, Corp.), and
fluorescence signals were recorded by the EMCCD camera’s onboard DAQ system. For each Mmode recording, PA signals before and after odor stimulation from a volume (~6 μm × ~6 μm ×
~200 μm) of neurons inside the brain tissue were acquired at a 1D imaging rate of 1 kHz. To form
a 3D image of the fly brain, 2D raster scanning was performed by motor stages. A photodiode
(not shown) was used to compensate for the laser pulse energy fluctuation.
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Figure 6.1 PAM of the GCaMP5G-expressing fly brain. (a) Schematic of the dual-modality PAM and epifluorescence microscopy (EFM) system. PAM and EFM share the same light path for excitation. While the
photoacoustic (PA) signal is detected by a ring-shaped ultrasonic transducer, the fluorescence signal is
detected by an EMCCD. (b) PAM image of a fly with endogenous contrast, showing the major parts of the
fly, including the antennae, compound eyes, head, and thorax. The PA signals mostly come from pigments
(e.g., melanin) on the fly cuticle.

Fly preparation and odor stimulation

GCaMP5G

flies

were

purchased

from

the

Bloomington Drosophila Stock Center at Indiana University. Flies were anesthetized by CO 2 until
their movement stopped, and were moved to a customized fly mount (a block setup 186 or a foil
setup187). For the block setup(Figure 6.1(a)), the fly was mounted and head-fixed using a twocomponent silicone glue (KWIK-SIL, World Precision Instruments, Inc.). A thin wire was used to
pull the antennae plate forward and make space between the antennae plate and the head. A small
rectangular hole was created on the bottom of a 60 mm × 15 mm petri dish (Falcon ®, Corning,
Inc.). Four sections of double-sided tape were used to create a rectangular window slightly larger
than the head of the fly. The petri dish with the small rectangular open window at the bottom was
placed on top of the fly’s head and fixed onto the mounting block by double-sided tape. The interior
rectangular edges were then sealed with two-component silicone glue. For the foil setup, a piece
of aluminum foil was glued to the top of a supporting plate. A 60 mm × 15 mm petri dish (Falcon®,
Corning, Inc.) with its bottom removed was attached to the top of the supporting plate to form a
saline chamber. A hole was made in the foil according to the fly’s size. The fly was then wedged
into the hole with its dorsal side facing upwards. The gap between the fly and foil was sealed using
epoxy (Permatex, Inc.). The ventral side, especially the antennae, of the fly was kept underneath
the foil. The fly was then transferred to the PA/fluorescence imaging setup for experiments with
the cuticle intact.
For experiments with the cuticle removed, a fine forceps (Dumont #5sf, Fine Science Tools, Inc.)
was used to cut and remove the cuticle above the brain. Connective tissue and the trachea above
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the brain were also removed. The petri dish was then filled with fly Ringer’s solution (103 mM
NaCl, 3 mM KCl, 5 mM TES, 10 mM trehalose, 10 mM glucose, 9 mM sucrose, 26 mM NaHCO 3,
1 mM NaH2PO4, 1.5 mM CaCl2, 4 mM MgCl2, adjusted to 275–280 mOsm, bubbled with 95%
O2/5% CO2) for acoustic coupling. Note that both during the preparation and during olfactory
stimulation experiments, the antennae remained completely dry. A constant air flow (carrier
stream; 0.8 L/min) was maintained across the fly antenna. For odor stimulation, a constant volume
of headspace (0.5 L/min) above an odor bottle containing ethyl acetate was injected into the carrier
stream.
PACT of acute mouse brain slices An optical parametric oscillator (OPO) laser (basiScan,
Spectra-Physics, Inc.), pumped by an Nd:YAG laser (Qsmart 850, Quantel, Inc.), provided 488nm-wavelength pulses with a 10-Hz pulse repetition rate. The laser beam was homogenized by an
optical diffuser (EDC-5, RPC Photonics, Inc.). The PA signals were detected by a full-ring
ultrasonic transducer array (Imasonic, Inc.) with a 10-cm diameter, 5-MHz central frequency,
>90% one-way bandwidth, and 512 elements. Each element (20-mm height, 0.61-mm pitch, and
0.1-mm inter-element space) was cylindrically focused to produce an axial focal length of 40 mm
(acoustic NA: 0.25). The combined foci of all 512 elements formed a field of view of ~20 mm
diameter with an approximately isotropic in-plane resolution of ~100 µm, while the elevational
resolution was ~1 mm. The wide-field imaging exposure time was under 20 µs with a frame rate
of 10 Hz. The raw data from each element was first Wiener deconvolved to account for the
ultrasonic transducer’s impulse response and then reconstructed based on the universal backprojection algorithm 188.
A brain slice holder made of 4% agarose was placed in the center of the imaging chamber of the
PACT system. A silicone tube was used for high-potassium perfusion (150 mM KCl
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concentration) in the imaging chamber. During imaging, the chamber was filled with regular aCSF
solution and continuously bubbled with 5% CO2 and 95% O2. A peristaltic pump circulated and
homogenized the aCSF solution within the imaging chamber.
Brain slice preparation

The protocol for mouse brain slice preparation was approved by the

Animal Studies Committee at Washington University in St. Louis.
Acute coronal brain slices were prepared from 3 months old GCaMP6f (C57BL/6J-Tg) mice,
which were purchased from the Jackson Laboratory. The GCaMP6f labeled mice were
anesthetized with isoflurane and decapitated. The brain was removed and glued onto a vibratome
(Leica VT1200s, Leica Microsystems, Inc.) specimen holder. Coronal slices (300 µm thick) were
cut in ice-cold modified aCSF solution (125 mM NaCl, 25 mM glucose, 25 mM NaHCO 3, 2.5 mM
KCl, 1.25 mM NaH2PO4, 0.5 mM CaCl2, and 3 mM MgCl2) equilibrated with 5% CO2 and 95%
O2. Slices were then transferred to choline-based aCSF solution (92 mM choline chloride, 2.5 mM
KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 5 mM Na-ascorbate,
2 mM thiourea, 3 mM Na-pyruvate, 2 mM CaCl2, and 1 mM MgCl2) equilibrated with 5% CO2
and 95% O2, incubated at 32°C for 30 min, and subsequently stored in regular aCSF solution (125
mM NaCl, 25 mM glucose, 25 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM CaCl2, and
1 mM MgCl2) equilibrated with 5% CO2 and 95% O2 at room temperature for more than an hour,
and imaged with the PACT system.
Wide-field fluorescence imaging of the fly brain and acute mouse brain slices

Wide-

field fluorescence imaging was performed on an Olympus Fluoview 1000 system (excitation
wavelength at 488 nm, emission filter wavelength centered at 510 nm; Olympus, Corp.). The
fluorescence images were captured by an EMCCD camera (iXon Ultra 888, Andor, Ltd.). A 10×
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water immersion objective (0.3 NA, UMPLFLN, Olympus, Corp.) was used for GCaMP5Gexpressing fly brain imaging. A 2× objective (0.14 NA, XLFluor2X/340, Olympus, Corp.) was
used for GCaMP6f-expressing mouse brain slice imaging.
Data analysis Image processing was performed in MATLAB (Mathworks, Inc.). In all
experiments, the baseline PA and fluorescence signals were calculated as the averaged signals
acquired before the simulation. The fractional changes in PA and fluorescence signals, compared
with the baselines values, were then calculated.

6.3 Results
6.3.1 PAM of GCaMP5G-expressing Fruit Fly Brains In Vivo
One challenge for imaging GCaMP in live brains with PAT is the interference signals from
hemoglobin, which has a strong optical absorption at the peak wavelength of the GCaMP
absorption spectrum (488 nm). To overcome this challenge 189 and unequivocally demonstrate the
feasibility of GCaMP imaging with PAT, we chose a simple and well-established transgenic
invertebrate model, Drosophila melanogaster (i.e., fruit fly), which does not have hemoglobin in
its brain. For the proof-of-concept experiments, we used a transgenic fly line that expresses
GCaMP5G pan-neutrally in all cholinergic neurons.
To image neural calcium signals in the fly brain, we developed a PA and epi-fluorescence dualmodality microscope (Figure 6.1(a),Methods). The dual-modality microscope can simultaneously
record the odor-evoked neural activities in the fly brain in vivo, with an automatically co-registered
field of view and complementary image contrasts. When a 488-nm–wavelength laser pulse excites
the GCaMP molecules in the brain, the captured laser energy is transformed partially into
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fluorescence signals and partially into PA signals, with a 67% fluorescence quantum yield 190. It is
worth noting that the ultrasonic transducer in our microscope temporally resolves PA signals from
different depths along the acoustic axis, and no additional depth-scanning is required. Moreover,
only a two-dimensional (2D) raster scan is needed for PAM to form a 3D image. The PAM system
and the epi-fluorescence microscopy (EFM) system share the same optical focusing pathway and
thus have the same lateral resolution. The axial resolution of PAM is acoustically determined,
while EFM lacks axial resolution over planar targets.
Using PAM, we first imaged the whole fly brain with the cuticle intact as well as the adjacent body
parts. A maximum amplitude projection (MAP) image clearly shows the brain cuticle, antennae,
compound eyes, and thorax (Figure 6.1(b), Methods). The strong PA signals mostly come from
the pigments of the cuticle. To gain direct optical access to neurons in the fly brain, we removed
the cuticle posterior to the two antennae and the underlying connective tissue surrounding the

Figure 6.2 Spectral characterization of a fly brain. (a) Cross-sectional photoacoustic microscopy images of
the brain at different depths, acquired at 488 nm. The cuticle was surgically removed. The labeled depths
indicate the axial distances from the brain surface. (b) PA spectrum (blue dots) of the fly brain, which
correlates well with the reported absorption spectrum (black curve) of GCaMP5G 190.
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brain186. The PA depth-resolved images of the exposed fly brain show heterogeneous GCaMP
expression levels in the brain (Figure 6.2(a)). The strongest PA signals came from putative neural
cell bodies. To confirm that the PA signal was generated by GCaMP, we used PAM to measure
the absorption spectrum of the brain tissue by tuning the laser wavelength from 410 nm to 550 nm
(Figure 6.2(b)). The spectrum measured by PAM agrees well with that measured purely optically
elsewhere190. This result is strong evidence that GCaMP is the major chromophore in the fly brain
in the visible spectral range. In addition, fluorescence signals from GCaMP were simultaneously
acquired by the EFM channel (Figure 6.3(a)) to further confirm the origin of the PA signals.

Figure 6.3 PA imaging of odor-evoked neural activity in the fly brain without and with cuticle. (a) Epifluorescence image of a GCaMP5G-expressing fly brain with the cuticle surgically removed. The dashed
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circle identifies the lateral location of M-mode PA recording. (b) Fractional PA amplitude changes from
representative neuron layers in the glomerular region of the fly antennal lobe, showing varied response
amplitudes and durations at different depths. Note that the depth in this panel is measured from the surface
of the fly brain. The gray bar indicates when a puff of ethyl acetate was delivered to the fly antenna. (c)
Averaged fractional PA amplitude response and the concurrently recorded fluorescence intensity response
to odor stimulation with the cuticle removed. (d) Epi-fluorescence image of a GCaMP5G-expressing fly
brain with the cuticle intact (i.e., not surgically removed). The lateral location of the M-mode PA recording
is marked by the dashed circle. (e) Fractional PA amplitude changes from representative neuron layers in
the fly brain with its cuticle intact. Note that the lack of response in the cuticle layer (CL) is shown here as
a control. Depth in this panel is measured from the cuticle layer. The gray bar indicates the duration of the
ethyl acetate delivery to the fly antennae. (f) Averaged fractional PA amplitude response from the fly brain
with intact cuticle and the concurrently recorded fluorescence intensity response to odor stimulation.
Although the fractional changes in PA amplitude and fluorescence intensity are comparable in magnitude,
depth-resolved measurements of neural activity were made only by the PA system.

We monitored neural activities in the fly brain evoked by a sensory stimulus. We administered a
5 sec. long puff of ethyl acetate to the fruit fly antenna while monitoring the changes in the GCaMP
signals in the glomerular regions of the antennal lobe (a region where olfactory sensory neuron
axon terminals converge and synapse with the downstream neural populations). M-mode recording
(i.e., repeated 1D depth-resolved PA imaging at the same lateral location) was performed in the
fruit fly antennal lobe. Depth-resolved PA signals from different layers in the brain (~200 µm
thick) were acquired at a 1D imaging rate of 1 kHz (Figure 6.3(b)). The increase in GCaMP’s
optical absorption coefficient led to the same fractional PA and fluorescent signal changes. In
response to the odor stimulation, we observed an ~23% PA signal increase on average (Figure
6.3(c)), which indicated elevated neural activities. The strongest fractional PA signal change
(~34%) was observed at 90 µm beneath the brain surface. We observed different response
durations at different depths from the PAM channel, which clearly indicates the heterogeneity in
the dynamics of odor-evoked responses from sensory neuron axonal terminals. Ethyl acetate
strongly activates different types of sensory neurons and in particular those housed in the large
basiconic sensilla. The axonal terminals of these sensory neurons are known arborize in different
glomeruli at different depths in the fly antennal lobe191,192 The PA response time course averaged
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over all depths correlates well with the fluorescence response (Figure 6.3(c)) simultaneously
recorded at the same lateral location. This correlation indicates that the same neuronal events were
being imaged by both PAM and EFM channels. More importantly, depth-resolved signals were
only obtained using PAM, clearly illustrating the benefit of the proposed approach. We also
recorded similar PA and fluorescence responses in the lateral horn region of the fly brain (Figure
6.4).

Figure 6.4 Fluorescence and PA recording of neural activities in the lateral horn region of a fly brain. (a)
Epi-fluorescence image of a GCaMP5G-expressing fly brain with cuticle removed. The location of the Mmode PA recording is marked by the dashed circle. (b) Averaged fractional M-mode PA signal change and
concurrent fluorescence response to odor stimulations in the fly brain, with cuticle removed.

Next, taking advantage of the depth-resolving and scattering-tolerant capabilities of PAM, we
sought to obtain whether such depth-resolved signals can be obtained from flies with intact cuticles
(i.e., without any surgical preparations) (Figure 6.3(d)). Although light was attenuated by the
cuticle and connective tissue, PAM still detected signals from all neuron layers in the brain. We
recorded concurrent M-mode PA and fluorescence signals upon odor stimulation . Similar to the
results acquired with the cuticle removed, different PA responses were recorded from different
neuronal layers (Figure 6.3(e)). The PA signals from the surface layer of the cuticle, served as a
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built-in control and indeed failed to show any changes during odor stimulation as expected. Note
that even with the intact cuticle, the fractional signal change was observed reliably (Figure 6.3(e)(f), Figure 6.5). Again, the PA results were confirmed by the concurrent fluorescence recording
(Figure 6.3(f)).

Figure 6.5 Odor-evoked maximum fractional change in PA amplitude in the fly brain, with removed and
intact cuticle, respectively. Error bars, standard deviations. n = 3.

As mentioned earlier, PAM can render a 3D calcium image with only a 2D scan. To illustrate this,
we imaged a volume of 100 μm (x axis) by 40 μm (y axis) by 270 μm (z axis) in the antennal lobe
region of the fly brain (with the cuticle removed), at a volumetric imaging rate of 1 Hz (Figure 6.6,
Figure 6.7). Both anatomical structures and the functional activity of neurons expressing
GCaMP5G in the putative glomerular layers of the fly antennal lobe were clearly imaged (Figure
6.6(a)). The diversity of odor-evoked responses at different depths were still captured (Figure
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6.6(b)-(c)). In sum, these results convincingly show that PAM can monitor depth-resolved calcium
signals from neurons with high spatial and temporal resolutions.

Figure 6.6 Volumetric PAM of odor-evoked neural activities in the glomerular antennal lobe region of a fly
brain. (a) Volumetric images of the fly brain with the cuticle removed, before, during, and after the odor
stimulation. The fractional changes in PA amplitude (shown in color) are overlaid on the structural image
(shown in gray). (b) Depth-wise averaged fractional changes in PA amplitude during odor stimulations.
The changes are averaged over the two stimulations. (c) Time courses of averaged fractional PA amplitude
changes from two representative layers (labeled in (a)) of neurons. The gray bars indicate two successive
puffs of ethyl acetate.
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Figure 6.7 Cross-sectional view of PAM of odor-evoked neural activity in the antennal lobe region of a fly
brain with the cuticle removed. (a) Cross-sectional structural image of the antennal lobe region of a fly
brain with the cuticle removed. (b) Fractional change in PA amplitude in the region shown in (a), during
odor stimulation. (c) Fractional change in PA amplitude overlaid with the cross-sectional structural image
of the fly brain.

6.3.2 PACT of Live GCaMP6f-expressing Mouse Brain Slices
Taking advantage of PACT’s deep imaging capability, we used our recently developed high-speed
PACT system to image neural activity at depths greater than the optical diffusion limit of ~1 mm
(Figure 6.8(a)). With wide-field illumination and parallel acoustic detection, the newly developed
PACT system features high spatiotemporal resolution, deep penetration, and full-view fidelity.
PACT acquires a 2D cross-sectional image with a 100-μm resolution at a 10-Hz frame rate.
Further, only a single laser pulse is used to generate each 2D image, and thereby greatly reducing
unnecessary light exposure and resultant photobleaching. In the absence of hemodynamically
induced PA signal changes in the brain slice, GCaMP6f is the chromophore that can generate
dynamic PA signals upon 488 nm laser excitation during neural activities.
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Figure 6.8 PACT monitoring of in vitro neural activities in GCaMP6f mouse brain slices. (a) Schematic of
the high-speed PACT system, with wide-field illumination and parallel acoustic detection. The GCaMP6fexpressing brain slice was immersed in regular aCSF solution in the imaging chamber. (b) PACT images
of the GCaMP6f-expressing brain slice in a clear medium (left) and through a 2-mm-thick scattering
Intralipid solution (right, reduced optical scattering coefficient 10 cm−1). (c) PACT of the neural activity
in a GCaMP6f-expressing mouse brain slice in response to high-potassium perfusion. The fractional PA
amplitude change (shown in color) is superimposed on the baseline image (shown in gray). (d) Time courses
of fractional PA amplitude changes from four representative regions (I, II, III and IV) as indicated in (c).
The solid lines are fittings using a bell-shaped dose-response model.

We imaged neural activity in acute coronal slices (300 μm thick) of a GCaMP6f-expressing mouse
brain. The brain slice was mounted in the PACT imaging chamber, which was filled with regular
artificial cerebro-spinal fluid (aCSF), and imaged either without any scattering medium or through
a 2-mm-thick tissue-simulating scattering medium (Figure 6.8(b)). In PACT images acquired
without an overlying scattering medium, major brain structures expressing GCaMP6f, such as the
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cortex and hippocampus, were clearly resolved. Notably, even when the brain slice was covered
with a 2-mm-thick scattering medium (1% Intralipid in deionized water, with a reduced scattering
coefficient ~10 cm−1), GCaMP6f-rich brain structures were still observable (Figure 6.8(b)).

Figure 6.9 Wide-field fluorescence microscopy of a GCaMP6f-expressing mouse brain slice. (a)
Fluorescence image of a GCaMP6f-expressing mouse brain slice, showing that the hippocampus area had
a high expression level of GCaMP6f. (b) Averaged fractional fluorescence intensity changes after highpotassium perfusion, from the three regions marked in (a). The short-period signal decrease right after the
perfusion started was due to optical defocusing caused by the perfusion perturbation.

To stimulate the neurons in the brain slice, we performed high-concentration potassium perfusion
in the PACT imaging chamber (Methods). The elevated extracellular potassium depolarized
neurons in the brain slice and induced action potentials. Upon high-potassium perfusion, increased
PA signals were recorded from multiple areas within the brain slice (Figure 6.8(c)). The fractional
PA amplitude changes shown in Figure 6.8(d) were averaged over representative regions of
interest. The fractional PA amplitude increased by up to ~15% during the potassium perfusion.
After the potassium perfusion, the intracellular calcium concentration gradually returned to the
baseline level through diffusion and sodium-calcium exchanges, resulting in decreased PA
amplitudes in the originally responding areas. In another experiment with a mouse brain slice
covered with 1.5-mm-thick mouse brain tissue, we also observed a similar PA signal increase upon
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high-potassium perfusion. The PA response was independently validated by monitoring the
fluorescence response of a brain slice in regular aCSF, measured with a commercial wide-field
fluorescence microscope. The same sample preparation and stimulation procedures were used
(Methods). In sum, our results confirm that PACT is a unique and effective calcium imaging
technique with an image depth beyond the optical diffusion limit.

6.4 Conclusions and Discussion
We have demonstrated, for the first time, that multiscale PAT can be used for imaging neuronal
calcium signals, with high spatiotemporal resolution and deep penetration. With fast dynamics,
high photostability, and a large fractional absorption response, GCaMP or its variants offers an
ideal optical contrast for PAT as PA signal is exquisitely sensitive to optical absorption. With the
depth-resolved imaging capability, we showed that PAM can perform fast 3D calcium imaging in
fruit flies expressing genetically encoded calcium indicators. Notably, using PAM we were able
to monitor depth-resolved odor-evoked neural activities from the fly brain, without the need for
invasive surgery, which could compromise experimental reproducibility 193. While we focused on
the feasibility of PAM for neural imaging here, the imaging rate can be readily increased by
utilizing a higher pulse-repetition-rate laser and an optimized scanning mechanism 5.
Optical scattering of light severely limits high-resolution optical imaging techniques to superficial
tissue layers. Our results clearly demonstrate that by utilizing diffused photons, PACT can image
neural responses beyond the optical diffusion limit. Prior work has shown that PACT can provide
a penetration depth of 8 mm in a rat brain168. Although, the imaging depth of PACT demonstrated
in this study was largely limited by the relatively short absorption wavelength of GCaMP, it can
be further improved by using calcium indicators that absorb strongly at longer
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wavelengths180,194,195, especially in the near-infrared wavelength region (700–1100 nm). The
combination of near-infrared calcium indicators and PACT can potentially enable small-animal
whole-brain neural imaging.
So far, a variety of imaging modalities have been explored for brain studies, especially two-photon
microscopy and functional magnetic resonance imaging (fMRI). At the microscopic scale, twophoton microscopy allows detailed and direct examination of neural activities in small animal
models

196

. At the macroscopic scale, fMRI has been extensively used to map human or large-

animal brain activities, allowing indirect coarse-grained localization of cognitive functions with
hemodynamic signals. However, correlating the two imaging scales still remains a major challenge
due to the different signal-contrast sources of these two modalities. Therefore, there is a gap in our
understanding between the macroscopic activity patterns in humans or large animals and the
microscopic activity details in small-animal models. PAT has been scaled up for multiplecentimeter penetration and can provide multiscale imaging for not only small animals but also
potentially large animals (at least with open skulls)59,158,197 . Multi-wavelength PAT can be
implemented to simultaneously record and unmix hemodynamic and calcium signals, enabling
studies of neurovascular coupling. Therefore, PAT is uniquely positioned to bridge this contrast
gap across the length scales, facilitating correlative neuroscience studies in various animal models
of brain diseases such as Alzheimer’s disease and stroke148.
In conclusion, we have shown that PAT holds great promise for neuronal calcium imaging in the
brains of transgenic invertebrate and vertebrate models expressing GCaMP indicators. With PAM,
we demonstrate in vivo high-resolution depth-resolved neural imaging without depth scanning,
which enables 3D imaging of neural activities at high temporal resolution. With PACT, we
demonstrate neural activity imaging with GCaMP beyond the optical diffusion limit. The
102

combination of advanced PAT technologies and genetically encoded neural activity indicators
optimized for PA imaging offers the neuroscience community a new methodology for studying
neural networks in vivo.

103

Chapter 7 Summary and Outlook
In this dissertation, we have applied novel PA contrasts for homogenous flow measurements, labelfree macrophage imaging, automated 3D cell nuclei imaging of whole organs, targeted
imaging/therapy of angiogenesis, and neural imaging of calcium/voltage signals in brains through
thick scattering medium.
In Chapter 2, with structured illumination, we demonstrated flow speed measurement in a
homogenous medium based on the photoacoustic Doppler frequency shift. Next, by optically
encoding a thermal pattern in the flowing medium, we successfully measured the flow speed in a
blood vessel in mouse ear vasculature in vivo.
In Chapter 3, we first demonstrated the use of PAM for spectral characterization of macrophages.
Then, with the assistance of a microtome, we demonstrated automated PAM of whole organs with
subcellular resolution.
In Chapter 4, we applied novel near-infrared copper nanoparticles for targeted imaging and therapy
of angiogenesis in mice in vivo for the first time.
In Chapter 5, we demonstrated the first use of DPA and characterized it for photoacoustic neural
imaging. We applied the dye to live cell imaging, and to in vivo mouse brain neural activity
imaging during epilepsy and cortical electrical stimulation.
In Chapter 6, on the microscopic scale, we unambiguously demonstrated PA imaging of a
genetically encoded calcium indicator in a fly brain without interference signals from hemoglobin.
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On the macroscopic scale, we demonstrated wide-field neural activity imaging of a live GCaMP
brain slice.
The exploration of novel contrasts of PAT is still going on. For endogenous contrast imaging, we
expect to include more endogenous contrasts, such as lipid in the near infrared range for label-free
mouse brain imaging, and specific biological molecules at their “fingerprint” wavelengths in the
mid-infrared range. By extending the wavelength palette from UV to mid-infrared, we expect to
provide a more complete map of biomolecules without labeling and with minimal processing.
With the development of more long-wavelength exogenous probes (dyes, proteins and
nanoparticles) for PA, we seek to push the penetration depth to above 1 mm in the mouse brain for
neural activity imaging in vivo, and to unambiguously un-mix dye/protein signals from
hemodynamic signals.
Combined with advanced contrasts, rapidly developing PAT systems with higher frame rates and
improved resolution, can potentially enable deep, fast, and high-resolution imaging of diverse
biological and physiological processes for basic neuroscience studies and preclinical/clinical trials
in cancer diagnostics/treatment and immunotherapy.
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